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Abstract 
Background: Decision-analytic models are used in the context of economic evaluation to 
bring together the best available evidence and to support the decision on the adoption of a 
health technology. A decision model’s credibility is, however, diminished by uncertainty 
which, to large part, stems from parameter uncertainty. Especially when novel technologies 
are evaluated, high quality evidence may not be available at the point of coverage decision 
making. A decision model incorporating uncertain parameter values eventually simulates 
uncertain effectiveness and cost outcomes. 
To enhance credibility of decision models, external validation of uncertain parameter values 
is vital. Data sources for external validation should be able to reflect the model’s study 
design and patient cohort, and estimate real-world effectiveness and costs.  
Objective: This study assesses whether claims data of health insurance funds are suitable to 
externally validate decision-analytic models. 
Methods: To answer the research question, a validation approach is developed which 
highlights critical steps in the validation of decision models based on claims data. The 
validation steps are: 1) selection of the validation level, 2) selection of the claims dataset, 
study design, and patient cohort, 3) selection of disease-relevant health technologies and 
costs, 4) statistical analysis of claims data, 5) changes to the decision model, 6) comparison 
between model and claims data, and 7) sensitivity analyses.  
The validation approach is exemplarily applied in the validation of a Markov model 
comparing treatment of localized prostate cancer (active surveillance and radical 
prostatectomy) in a German health care context, based on claims data of the German AOK 
statutory health insurance fund. An external validation of resource use, probability of 
utilization, and cost parameters is chosen, because these parameters are afflicted by a high 
degree of uncertainty in the decision model.  
Two different approaches to the analysis of relevant health technologies for prostate cancer 
treatment are presented in claims data analysis: an excess approach and a disease-related 
approach.  
Results: The decision model assumes that resource use and unit costs are identical in the 
two treatment groups; this is, however, not observed in claims data analysis.  
 
Excess cost analysis and disease-related cost analysis of AOK claims data as well as model 
analysis show that, overall, active surveillance is the less costly strategy compared to radical 
prostatectomy, with total incremental costs of €-6,611, €-6,260, and €-7,486 respectively. 
When testing differences between model and outcomes of claims data analysis, p-values of 
0.61 (excess approach) and 0.18 (disease-related approach) indicate an agreement that is 
sufficient to assume that the decision model simulates real-world costs validly. 
Discussion: This study reveals general strengths and limitations of claims data based model 
validation.  
Claims data are able to provide evidence on real-world resource utilization and, with 
limitations regarding clinical information, effectiveness of a wide range of indications and 
treatments for a large patient cohort. Validation based on claims data is especially suitable 
when the decision maker, interested in the validity of the model in question, is the insurance 
fund providing access to the claims data.  
Suitability of claims data based validation is, however, limited concerning the replication of 
decision models’ structure and patient cohort. For one, the identification of distinct health 
states is limited, because clinical information is not included in sufficient detail. Secondly, 
due to non-randomization and a restricted number of variables available to adjust for 
confounding, comparability of treatment groups is limited in claims data analysis. Thirdly, 
distinct identification of health technology utilization and corresponding costs is not possible 
if the technology of interest is not specifically coded. Finally, claims data are, generally, 
collected for billing purposes; diagnoses and technology utilization are only coded if they are 
relevant for reimbursement by the insurance fund, which biases outcomes of model 
validation in cases where treatment is not covered by the insurance fund. 
Conclusion: The presented validation approach indicates critical aspects of the validation 
based on claims data, which may support researchers and decision makers in their decision 
on the suitability of claims data for model validation.   
The suitability of claims data for the external validation of a decision model ultimately 
depends on the ability of the claims data source to reflect the model’s patient cohort and 
outcome measures. 
Zusammenfassung 
Hintergrund: Entscheidungsanalytische Modelle kommen im Rahmen der 
gesundheitsökonomischen Evaluation von Gesundheitstechnologien zum Einsatz, um die 
beste verfügbare Evidenz zusammenzuführen und damit die Erstattungsentscheidung zu 
unterstützen. Bei der Evaluation von innovativen Technologien ist allerdings häufig zum 
Zeitpunkt der Erstattungsentscheidung keine hochwertige Evidenz, etwas aus klinischen 
Studien, verfügbar. Diese Parameterunsicherheit spiegelt sich letztlich in der im 
Entscheidungsmodell simulierten Kosteneffektivität der jeweiligen innovativen Technologien 
wieder. Für den Entscheidungsträger ist somit die Glaubwürdigkeit von 
Entscheidungsmodellen eingeschränkt.  
Um die Glaubwürdigkeit eines Entscheidungsmodells zu erhöhen, ist eine externe 
Validierung der unsicheren Parameterwerte von entscheidender Bedeutung. Datenquellen 
für eine externe Validierung sollten in der Lage sein, das Studiendesign und die Kohorte des 
Entscheidungsmodells zu reflektieren sowie reale Effekte und Kosten der evaluierten 
Technologie zu schätzen. 
Fragestellung: Im Rahmen dieser Studie wird untersucht, in wie weit sich Abrechnungsdaten 
von Krankenkassen für die externe Validierung von entscheidungsanalytischen Modellen 
eignen. 
Methoden: Um die Forschungsfrage zu beantworten, wurde ein Validierungsansatz 
entwickelt, welcher entscheidende Schritte bei der Validierung von Entscheidungsmodellen 
auf der Basis von Abrechnungsdaten beschreibt. Die einzelnen Validierungsschritte sind: 1) 
Auswahl der Validierungsebene, 2) Auswahl des externen Datensatzes, des Studiendesigns 
und der Patientenkohorte, 3) Definition von krankheitsrelevanten Gesundheitstechnologien 
und Kosten, 4) Auswahl der statistischen Methoden zur Analyse der Abrechnungsdaten, 5) 
Anpassung des Entscheidungsmodells, 6) Auswahl von Methoden zum Vergleich zwischen 
Modell und Abrechnungsdaten, und 7) Sensitivitätsanalysen. 
Der Validierungsansatz wird beispielhaft für die Validierung eines Markov-Modells 
angewendet, welches Behandlungsmethoden des lokalisierten Prostatakarzinoms (Active 
Surveillance und radikale Prostatektomie) in einem deutschen Versorgungskontext 
vergleicht. Zur Validierung werden Abrechnungsdaten einer deutschen gesetzlichen 
 
Krankenkasse, der AOK Baden-Württemberg, herangezogen. Es werden Parameterwerte des 
Entscheidungsmodells zum Ressourcenverbrauch, zur Inanspruchnahmewahrscheinlichkeit 
und zu Kosten validiert, da diese Parameter die größte Unsicherheit aufweisen. Dabei 
werden zwei verschiedene Vorgehensweisen zur Analyse der Abrechnungsdaten der AOK 
herangezogen: ein Excesskosten-Ansatz und ein Krankheitskosten-Ansatz. 
Ergebnisse: Im Entscheidungsmodell wird davon ausgegangen, dass Ressourcenverbrauch 
und Stückkosten in beiden Behandlungsgruppen identisch sind; in den Abrechnungsdaten 
der AOK ist diese Annahme allerdings nicht wiederzufinden. 
Sowohl die Excesskosten-Analyse und die krankheitskostenbezogene Analyse der AOK-Daten 
als auch die Modellanalyse zeigen, dass Active Surveillance insgesamt die kostengünstigere 
Strategie mit einer Ersparnis von jeweils 6.611€, 6.260€ und 7.486€ gegenüber der radikalen 
Prostatektomie ist. Der statistische Test der Kostendifferenz aus Modell und AOK-Daten 
ergibt p-Werte von 0,61 (Excesskosten-Ansatz) und 0,18 (Krankheitskosten-Ansatz), die auf 
eine signifikante Übereinstimmung der Schätzer aus Modell und AOK-Daten schließen 
lassen. Die Übereinstimmung der Schätzer lässt vermuten, dass das Entscheidungsmodell in 
der Lage ist, die Kosten der Behandlung des lokalisierten Prostatakarzinoms valide zu 
simulieren. 
Diskussion: Die beispielhafte Validierung des Markov-Modells anhand von 
Abrechnungsdaten der AOK Baden-Württemberg zeigt allgemeine Stärken und Schwächen 
der Kassendaten-basierten Modellvalidierung auf. 
Abrechnungsdaten sind in der Lage, Evidenz zur tatsächlichen Utilisierung von 
Gesundheitsleistungen und, mit Einschränkungen in Bezug auf klinische Informationen, 
Wirksamkeit einer Vielzahl von Behandlungsoptionen für eine große Patientenpopulation zu 
liefern. Die Validierung auf Basis von Abrechnungsdaten ist vor allem sinnvoll, wenn die 
Modellvalidierung aus der Perspektive einer Krankenkasse durchgeführt werden soll. 
Die Eignung von Abrechnungsdaten für die Modellvalidierung ist jedoch hinsichtlich der 
Nachbildung der Modellstruktur und der Patientenkohorte des Entscheidungsmodells 
limitiert. Erstens ist die Identifikation von Gesundheitszuständen in Kassendaten begrenzt, 
da klinische Informationen nicht ausreichend detailliert enthalten sind. Zweitens ist die 
Vergleichbarkeit der Behandlungsgruppen eingeschränkt, da eine Randomisierung nicht 
möglich ist und nur eine begrenzte Anzahl an Variablen zur Verfügung steht, um für 
Confounder zu adjustieren. Drittens ist eine eindeutige Identifizierung von 
Gesundheitsleistungen und deren Kosten schwierig, wenn die Leistung nicht explizit in den 
Abrechnungsdaten kodiert ist. Viertens werden Kassendaten zu Abrechnungszwecken 
gesammelt und deshalb werden auch nur solche Diagnosen und Gesundheitsleistungen 
kodiert, die für die Erstattung durch die Krankenkasse relevant sind. Für 
Gesundheitsleistungen, die nicht von der Krankenkasse vergütet werden, ist unter 
Umständen keine valide Schätzung zu Ressourcenverbrauch und Kosten möglich. 
Fazit: Der entwickelte Validierungsansatz zeigt kritische Aspekte der Modellvalidierung auf 
Basis von Abrechnungsdaten von Krankenkassen auf. Er soll Wissenschaftler und 
Entscheidungsträger bei der Entscheidung über die Eignung von Abrechnungsdaten für die 
externe Validierung eines Modells unterstützen. 
Die Eignung von Abrechnungsdaten für die externe Validierung eines Entscheidungsmodells 
hängt letztlich von der Fähigkeit ab, Modellstruktur, Kohorte und Zielparameter des Modells 
abzubilden. 
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1 Background and objective 
1.1 Decision-analytic modeling 
1.1.1 Modeling in health economic evaluations 
Economic evaluation in health care is defined as the comparison of alternative health 
technologies regarding their costs and consequences (1). The term ‘health technologies’ 
refers to a range of health care resources including medical devices, pharmaceuticals, 
procedures, organizational support systems, screening, and health promotion programs (2).  
The most frequently used types of economic evaluation include cost-effectiveness analysis, 
cost-utility analysis, and cost-benefit analysis (1). In cost-effectiveness analysis consequences 
are measured in natural units, for example the life years gained by an intervention. The 
alternative technologies are then compared by the calculation of an incremental cost-
effectiveness ratio (ICER). Cost-utility analysis allows comparison of interventions with 
different health outcomes by a single parameter – the utility. The standard measure for 
utility in health economics are quality-adjusted life years (QALY). QALY allows incorporation 
of life time and quality of life effects in a single outcome measure. Alternatives are, again, 
compared by the ICER (costs per QALY). Cost-benefit analysis measures consequences in 
monetary units. The decision to implement a health technology is positive if its monetary 
benefit exceeds the costs (1). 
Economic evaluation is used to inform decision makers about which health technologies to 
fund from available resources. This requires an incorporation of all adequate evidence in the 
evaluation to compare new technologies with all relevant alternative technologies. To come 
to a valid decision, it is also necessary to reveal uncertainty in evidence which can be 
addressed in future research (1). Randomized controlled trials (RCT) or observational studies 
can hardly accomplish these requirements independently, which provides a strong rationale 
for decision-analytic modeling as a framework for economic evaluation.  
Models bring together the best available evidence and systematically address uncertainty in 
threshold and sensitivity analyses (2). Decision-analytic models also allow evaluation of cost-
effectiveness of novel health technologies at an early stage of the development process 
where evidence from clinical trials is not available yet (3).  
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The two most frequently used types of decision-analytic models are decision-trees and 
Markov models. A decision-tree is the simplest form of a decision-analytic model. It is the 
visual representation of all possible options and the consequences following these. 
However, in case of indications with recurring events and lifetime analysis – such as prostate 
cancer – decision-trees become very complex. Markov models address this complexity by 
modeling events as transitions between defined health states (Markov states) in defined 
time intervals (cycles). Markov models take dates of events into account; time-dependent 
event probabilities as well as costs can be modeled (4). 
1.1.2 Evidence sources 
The best available evidence incorporated in a decision model usually stems from a variety of 
evidence sources and is used with different purposes within the model. Primary and 
secondary data sources can be incorporated in a decision-analytic model.  
In the design and specification of the model, evidence is used which describes the 
epidemiology of the underlying indication and its clinical care as well as clinical outcomes 
and resource use. Information on this is drawn from a range of evidence sources including 
RCTs, clinical guidelines, and administrative data sources (5). Evidence on clinical outcome is 
often found in RCTs and meta-analysis. In addition to primary evidence sources, national 
reimbursement catalogues (e.g. the German diagnosis related group (DRG) catalogue for 
inpatient costs) are frequently used to inform cost parameters (5, 6).  
The relevance of administrative data and reference sources, such as reimbursement 
catalogues, is often specific to the decision-making context, concerning geographical or 
reimbursement process features (5). Expert opinion is a common method used in the 
population of model parameters if no other evidence source is available. Expert estimates 
derived from formal methods such as Delphi or Nominal Group techniques are preferable to 
non-formal methods (6, 7). Reasonable effort to obtain new additional data prior to 
modeling should be considered. However, cost and delay in obtaining the data must be 
weighed against the benefit of reduction in uncertainty (7). 
1.1.3 Uncertainty 
Combining evidence on alternative health technologies from different evidence sources in 
decision models is a process that is inherently uncertain, because there will hardly ever be 
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complete information on all the possible cost and consequences of a technology in a given 
population (8). Especially at the time of introduction of a novel health technology, evidence 
which is relevant for the design of the model, such as treatment practice, patients’ 
compliance, as well as effectiveness and cost outcome, is usually scarce (9).   
The following types of uncertainty in decision models are described in the literature:  
o Methodological uncertainty includes uncertainty about the decision-making 
perspective, time horizon, or discount rate assumed in the model (2).  
o Structural uncertainty refers to uncertainty about the extent to which the structure 
of the model adequately captures relevant characteristics of the disease and health 
technology being investigated. This includes, for example, uncertainty about which 
disease states to incorporate or whether transitions between particular disease 
states are possible from a clinical point of view (8). 
o Parameter uncertainty describes the uncertainty about the value of each parameter 
of the model. This uncertainty arises from various sources. Uncertainty due to 
variability between individuals occurs by chance and cannot be addressed by 
generating further evidence. Parameter uncertainty may also arise from a lack of high 
quality evidence or an imprecision in measuring parameters which can be mitigated 
by further evidence collection (2). This is especially the case for novel health 
technologies which are not yet regularly used in clinical practice and for whom no 
evidence on effectiveness and costs is available. 
The overall uncertainty a decision maker is faced with, when deciding on the adoption of a 
novel technology, arises from the extent of methodological, structural, and parameter 
uncertainty in the decision model. To quantify the influence of parameter uncertainty on 
outcomes, probabilistic analysis methods have been developed, where variability of 
parameters is reflected by distribution functions; single or multiple parameters may be 
changed in the analysis (2). Further methods for quantifying uncertainty in decision-analytic 
models have been described in detail elsewhere (8). 
The credibility of the model in simulating outcomes which are relevant for the decision 
maker is, however, not established by quantifying uncertainty. This lack of trust is one of the 
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greatest challenges facing decision-analytic modeling; if it is not overcome decision makers 
may dismiss models as generally untrustworthy (9, 10).  
To assess how believable a model is and whether a coverage decision can be based on it, a 
sound validation of the model is necessary. Types of model validity and validation 
techniques are described in the following chapter.  
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1.2 Validation of decision-analytic models 
1.2.1 Levels of model validity 
Levels of model validity have been identified in the literature, but definitions do not always 
overlap (11-16). Here the definition, proposed by the joint modeling good research practices 
task force of the International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) and the Society for Medical Decision Making, is used (16): 
o Face validity refers to the extent to which a model and its assumptions and 
applications correspond to current science and evidence as judged by experts.  
o Internal validity describes the extent to which the mathematical calculations are 
performed correctly and are consistent with the model’s specifications.  
o Cross validity determines to which extent the decision model calculates same results 
as other models evaluating the same technology.  
o External validity refers to the extent the model is able to simulate real-world 
outcomes from actual event data. External validity can refer to the model as a whole 
or to some components of it.  
o Predictive validity describes whether the model is able to forecast actual events 
which are reported in observational studies and RCTs. 
External and predictive validity of a decision model are most critical for the decision maker 
because they closely correspond to the model’s purpose to anticipate what will occur if 
decision makers adapt a novel technology (16). 
1.2.2 Levels of model validation 
Philips et al. (2006) propose a framework for the quality assessment of decision-analytic 
models, which is not only a supporting tool for readers, but also a guideline for researches 
building models (17). It presents a literature overview of recommended validation 
techniques. 
Face validity may be assessed by the modeling team in accordance with clinical experts to 
assess whether the model’s structure corresponds to current research.  
It is recommended that the mathematical logic of the model (internal validity) is tested by 
sensitivity analyses, where null or extreme values are used for some parameter inputs and 
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the direction of results is examined based on these. The model might also be programmed in 
an alternative software package or by another researcher (6, 18). 
Comparing model outcomes with other decision-analytic models (cross validation) increases 
confidence. However, these tests may not be helpful if models are not independent and are 
all built on the same flawed assumptions (19).  
External validity can be addressed by comparing final or intermediate model results with 
available, independent evidence. External validation is performed based on formal data 
sources, which are generated for the purpose of model validation, or informal (secondary) 
data sources. Depending on the extent to which the original model is based on information 
from the data source that is used for validation, the validation is called dependent or 
independent. Data should not be withheld from the model for the purpose of external 
validation, though (6, 19). Published validation examples show that observational data from 
medical records or claims data as well as RCT data are used for external validation (20-25). 
In predictive validation the model is used to forecast events and, after some time, the 
forecasted outcomes are compared to the actual ones. Whether predictive validity of a 
model should be tested is discussed controversially in the literature. Some guidelines 
suggest that a model should demonstrate predictive validity (26, 27). Other authors 
conclude that some decision-analytic models are intended to support decisions at a 
particular point in time and not necessarily to predict future outcomes (6, 18).  
Generally, the value of the information obtained by external and predictive validation must 
be weighed against the costs of obtaining it (19). External and predictive validity are the 
most difficult levels of validation as real-world data are often scarce or costly and time-
consuming to collect (16). Also, external and predictive validation are methodologically the 
most critical part of model validation, because it involves the comparison of either outcomes 
of different models or comparison of model outcomes with outcomes found in the external 
data source. In the following, techniques for the validation of decision models based on 
external data sources are described. 
1.2.3 External validation techniques 
Two general approaches to external validation of decision models are identified in published 
model validations. In the first approach, the decision model simulates interventions, 
randomization into treatment groups, and follow-up according to the protocol of the study 
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that is employed for external validation. The decision model is run with parameter values 
extracted from the external trial; finally observed trial outcome and predicted model 
outcome based on trial data are compared (21-24). The second approach compares 
outcomes independently observed in the trial and predicted in the decision model. Evidence 
from the external trial is not incorporated in the decision model (20, 25). 
Furthermore, the decision on validation based on published evidence or evidence generated 
for the purpose of model validation influences the validation approach. In validation studies, 
where external data stem from published studies, the decision model has to be adapted to 
the external data source; study design and cohort selection cannot be influenced in the 
external data source (22-25). Published studies are reproduced in the model by recreating 
cohorts in terms of demographics, baseline risk factors and complications, treatment 
patterns and patient management strategies (21-24).  
When external validation is based on evidence generated for the purpose of model 
validation, the decision model’s structure and outcome can be replicated in the external 
data source. The study by Ishida et al. (2008), for example, analyzes medical records 
according to the patient characteristics and study design of the validated decision model 
(20). More comprehensive information on patient characteristics, diagnostics, and resource 
utilization in the external data source allows a more precise replication of model 
assumptions.    
ISPOR guidelines for model validation stress the importance of quantitative assessment of 
how well the model’s results match the externally reported outcomes (16). The motivation is 
to determine whether differences observed between the model and external data source 
are significant enough to affect any conclusions derived from the model. A variety of 
quantitative measures are proposed in the literature, but the specific choice of measure 
applicable to the present validation is not readily apparent. Additionally, the interpretation 
of some quantitative measures of goodness of fit is unclear. Percentage errors estimated for 
decision models, for example, need to be interpreted in relation to other model outcomes, 
because from the absolute numbers no inference on goodness of fit is possible (22, 28). 
A simple way to compare estimates of the external data source with the decision model is a 
graphical display of observed and simulated outcomes. To compare survival outcomes the 
comparison of Kaplan-Meier curves is applied in the literature (20, 23). For comparison of 
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cost outcomes, the output of the external data source and the decision model may be 
plotted in form of histograms such that the horizontal axis denotes costs and the vertical axis 
denotes the observed and simulated values, respectively (29, 30). 
Statistical tests are proposed in addition to graphical analysis to obtain quantitative 
information about the validity of the decision model. Several studies test the null hypothesis 
of no difference between observed and predicted outcomes with the Student t-test (22, 29). 
The problem with the t-test is, however, that on the one hand the difference between 
observed and simulated estimates can never exactly be zero; on the other hand, the bigger 
the sample size is chosen, for example during bootstrapping, the smaller the critical value of 
the t-statistic becomes, which in turn means that a simulation model has a higher chance of 
being rejected as its sample size gets bigger. The t-statistic may, consequently, show a 
significant difference of observed and simulated estimates and yet make no statement about 
the validity of the decision model in simulating observed outcomes. If the sample is very 
large the t-statistic is nearly always significant for the difference of estimates being unequal 
to null. This is also called a type I or alpha error; the model is rejected while the model is 
valid (29).  
Test-statistics other than the t-statistic are also described in the literature. These include the 
corrected Chi2-test, as well as nonparametric statistical tests such as the Wilcoxon signed-
rank test as a test of systematic error and Spearman’s correlation coefficient for continuous 
variables (23, 31). 
Alternatively, a hypothesis test based on bootstrapping can be employed, where it is tested 
whether the point estimate of the external data source is included in the model’s confidence 
interval (CI) and the other way round (22, 25, 30). That way the problem of the t-test is 
avoided and no assumptions on the distribution of estimates are necessary, as in the Chi2-
test.   
Also, the difference in outcome may be tested against a threshold – defined as the 
difference which is just acceptable to conclude that outcomes of claims data analysis and 
model simulation are comparable – because even in the best model results between actual 
treatment and model will deviate to a certain degree. However, determination of this 
threshold can only be based on subjective criteria (e.g. a deviation of less than 10% of 
outcomes estimated in claims data). 
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Furthermore, linear regression analysis is proposed in the literature to compare observed 
and simulated outcomes (22, 24, 32). Closeness of fit is assessed by plotting outcomes 
predicted by the model versus observed outcomes reported in the external data source, by 
fitting a linear curve through the points with the intercept set at zero. A squared linear 
correlation coefficient is obtained which provides an index of the degree to which the paired 
measures co-vary. It is then tested whether the linear correlation coefficient is larger than 
null; the simulated and real response may not necessarily have the same mean, but they 
may be positively correlated. A prerequisite for regression analysis is that pairs of patients 
(paired observations) are present in model simulation and observed data (e.g. by matching 
exact pairs from model and claims data).  
Studies comparing outcomes from different models apply goodness of fit tests to assess 
validity of the validated model (22, 33). These include the mean absolute percentage error 
and the root mean square percentage error. 
As described previously, external validation can be based on published data sources or on 
data sources which are generated for the purpose of model validation. A published external 
data source is usually not a gold standard when compared with model outputs. This is 
because the purpose of the model is to support decision making, which is usually not the 
purpose of a clinical or observational study (6, 19). 
Data sources generated for the purpose of model validation may origin in primary data 
collection, such as RCTs, or in secondary data sources such as registries or administrative 
data bases. The information included in different data sources can be the gold standard for 
different model perspectives; registries might, for example, provide evidence for models 
with a focus on effects in the general population. On the other hand, administrative data, 
especially claims data, might be valuable to provide evidence for models with a health 
insurance perspective. 
In the following chapters the use of claims data as a secondary data source in health 
economic research is described.   
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1.3 Claims data as a secondary data source 
1.3.1 Definition 
Secondary data in research are data which have not been collected with a specific research 
purpose. Such data are collected for management, administration or planning purposes, for 
the evaluation of activities within health care, for control functions, and in line with 
registries for surveillance purposes (34, 35).  
Claims data are a secondary data source because they are collected with the purpose of 
billing health care provision at the expense of health insurance funds. Claims data are in the 
following defined as routinely collected data from various health care service categories 
(inpatient care, outpatient care, pharmaceuticals, physiotherapy, assistive technologies, and 
rehabilitative care), as well as basic information on characteristics of insured individuals, 
such as age, gender, and insurance status (36). 
1.3.2 Claims data in health economic research 
The ISPOR task force on real-world data developed a framework to assist health-care 
decision-makers in dealing with real-world data, including claims data. The report states that 
real-world data are essential for sound coverage and reimbursement decisions. Decision 
analytic models are the primary tool for combining clinical and claims data. Real-world data 
are also needed in assessing the post-launch cost-effectiveness of novel technologies to 
update the modeling outcomes which are made to support the initial coverage and 
reimbursement decisions  (37). 
The strength of secondary data generally lies on the generation of effectiveness evidence for 
the population that is of interest for the decision maker. While RCT data typically are 
considered as the gold standard for evidence generation on efficacy in a particular group or 
subgroup, they are insufficient to project the size of the effectiveness impact on the whole 
population (38, 39). The particular strength of claims data is the data’s ability to display 
utilization of medical technologies in routine care and real-world cost data incurred by 
insurance funds (40). 
Another advantage of using secondary data sources is that they already exist and the time 
spent on the study is therefore likely to be considerably less than on studies based on 
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primary data collection (35). Especially in the coverage decision-making process, where a 
timely generation of evidence is of importance, use of secondary data sources is useful (37). 
Furthermore, study costs are significantly reduced compared with collection of primary data 
(35). 
A particular advantage of the use of claims data is the size of the covered population, which 
allows researchers to identify rare events and assess economic impact of various 
interventions (37). Furthermore, collection of claims data does not impose an additional 
burden on patients and clinicians, in contrast to clinical trials and registries (41). 
Limitations of secondary data sources regarding data quality include missing data, coding 
errors, and the lack of comprehensive data across health care service categories. Claims data 
are especially limited in the extent of clinical information on inpatient stays, health 
outcomes, health status, and symptoms. A distinction between costs and charges might in 
some cases be not possible based on claims data (37). Completeness of claims data is limited 
to those who seek care in the first place and additionally obtain care through the insurance 
fund (42). Generally, claims data are not collected for clinical research and coding practice 
might follow economic incentives of the underlying reimbursement system (40, 43). 
The most common and challenging methodological issue arises from treatment selection 
bias. Due to non-randomization, estimates of effects and costs can be biased because of a 
correlation between unobserved factors associated with treatment selection and outcome, 
for example the baseline health status (37). Matching-techniques and other statistical 
methods can be used to mitigate this bias (44). 
General limitations of claims data compared to primary data collection and techniques to 
handle these have been discussed extensively (40, 44-49).  
1.3.3 German statutory health insurance claims data 
In Germany, claims data of statutory health insurance (SHI) funds are a valuable source of 
evidence for research, because medical care, resource use, and reimbursement are 
documented in detail and over a long period of time for a large cohort of patients.  
About 85% of the German population is insured within the social security system of SHI. The 
remaining 15% of the population are covered by private insurance. The German statutory 
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health care system is characterized by pay-as-you-go financing and income-based insurance 
contributions. All SHI schemes are regulated by the Social Code Book V (SGB V). The SHI 
funds are responsible for negotiating prices, quantities, and quality assurance measures with 
providers on behalf of their members (50). 
SHI covers inpatient and outpatient care, pharmaceuticals, medical devices, assistive 
technologies, physiotherapy, (ambulatory) rehabilitative care, and sickness benefits. Co-
payments of patients are compulsory, especially for pharmaceuticals and assistive 
technologies. A small part of health-related social services is covered by accident insurance, 
retirement insurance, and long-term care insurance. Services covered by these funds are not 
documented in SHI claims data (50). 
In SHI claims data, diagnostic information is coded by the German application of the 
International Classification of Disease, version 10 (ICD-10 GM). In outpatient care, the 
certainty of the diagnosis is stated by an additional code (secured: G, tentative: V, exclusion: 
A, status post: Z). In inpatient care information is given on the point in time during the 
hospital stay and the department by which the diagnosis was coded and whether it is the 
primary or secondary diagnosis. Inpatient procedures are coded by operation and procedure 
codes (OPS) and reimbursement of these is reflected in DRGs. Outpatient procedures and 
reimbursement of these are found in the uniform value scale (Einheitlicher 
Bewertungsmaßstab, EBM) for SHI physicians. Pharmaceuticals are distinctly coded by a 
uniform pharmaceutical identification key (Pharmazentralnummer, PZN); assistive 
technologies and physiotherapeutic procedures have distinct codes as well (51). 
Due to the administrative nature of the data, only SHI relevant hospital episodes and 
outpatient visits are coded (52). Additionally, SHI claims data contain basic information on 
date of birth, gender and place of living, whereas more sophisticated socio-demographic 
information (household size and income, education, occupation) is not comprehensively 
documented for all insured individuals. Reasons for dropout are also coded which could be 
death or transition to another insurance fund. 
Cost data are available for inpatient and outpatient care, as well as pharmaceuticals, 
physiotherapy, assistive technologies, and rehabilitation on a patient level in SHI claims data.  
Complete inpatient data have to be reported to sickness funds immediately after discharge 
(53). Outpatient data are usually delayed by about six months as they are transferred over 
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the association of SHI physicians to sickness funds. Diagnostic information in outpatient data 
is, in general, summarized on a quarterly basis per patient, whereas inpatient data are 
reported on a hospital-episode basis per case (54, 55).  
Confidentiality issues are to be considered when patient data are not anonymous or 
pseudonymization is not possible. In such cases ethics approval and/ or the approval of the 
data protection agency as well as informed consent of affected patients is necessary to use 
claims data for research (56).  
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1.4 Objective 
Decision-analytic models are developed to inform decision-makers about adoption and 
reimbursement of novel health technologies in treatment practice. Uncertainty about the 
validity of decision models and generalizability of simulated outcomes, however, limits the 
credibility of models for decision making. Validation is essential to establish trustworthiness 
of decision-analytic models in the decision making process.   
Independent external data sources for validation are, however, often scarce. During model 
building not only a trade-off between incorporation of all best available evidence and 
exclusion of data sources for the purpose of external validation has to be made. Also, 
generation of primary data with the aim of model validation is usually costly and time-
consuming, especially evidence from clinical trials. 
This study assesses an alternative to external validation of decision-analytic models with 
primary data sources – external validation based on claims data of health insurance funds.  
The underlying assumption is that claims data represent the gold standard for real-world 
resource use and costs incurred by health insurance funds. Outcomes from claims data are 
representative for the study population most relevant to health insurance funds, which 
make the decision to reimburse a novel technology. Analysis of claims data for the purpose 
of model validation is, also, less costly and realized in a timelier manner than clinical trials.  
A validation approach is developed which highlights critical steps in the external validation 
based on claims data. The validation approach is exemplarily applied to the external 
validation of a Markov model comparing treatment options of localized prostate cancer in a 
German health care context. It is validated based on claims data of a large German SHI fund.  
The claims data set is used to build a cohort reflecting the model population as closely as 
possible. Input parameters for unit costs as well as resource use and treatment costs 
accumulated over the study duration are estimated in the claims data analysis. Comparison 
with model outcomes is based on statistical tests, with the underlying hypothesis that costs 
simulated by the model are equal to the costs observed in claims data.  
The focus of this study lies on the methodological approach to the external validation based 
on claims data. Application of the validation approach to other health care systems and 
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medical indications is discussed in detail. Strengths and limitations of claims data based 
validation are presented to answer the research question:  
‘Are claims data of health insurance funds suitable to externally validate decision-analytic 
models?’ 
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1.5 Structure of the dissertation 
Chapter 2 gives an introduction to the example of use – localized prostate cancer (PCa). 
Disease background including epidemiologic and socioeconomic burden as well as 
diagnostics and disease classification are presented. Treatment options for localized PCa, 
evidence on comparative effectiveness, and cost studies are summarized. Finally, the 
structure, basic assumptions, and data sources of the validated Markov model, comparing 
costs and utilities of treatment of localized PCa by Koerber et al. (2014), are described. 
The main focus of this study lies on chapter 3, where the methods of validation are 
described. Chapter 3.1 presents an overview of the proposed step-wise validation approach, 
whose implementation is described on the exemplary validation of the model by Koerber et 
al. (2014) in the chapters 3.2 to 3.8. 
First, the selection of the validation level is presented. Then, study design and methods for 
cohort selection in the claims dataset are described, which allow creation and follow-up of a 
patient cohort comparable to the Markov model. Special attention is given to the selection 
of procedure and diagnostic codes in the claims data that reflect disease-related resource 
use and costs assumed in the model. Statistical methods for calculation of resource use and 
costs in claims data are described separately for an excess cost and a disease-related cost 
approach. Changes to the Markov model’s runtime and age structure of the cohort are 
described in line with additional model analyses conducted to gain resource use and cost 
outcomes in a comparable format to outcomes from claims data analysis. In chapter 3.7 
methods for comparison of input parameter values for unit costs in the Markov model and 
unit costs calculated in claims data is presented. Also, methods to compare costs and 
resource use simulated by the model against observed outcomes of claims analysis are 
described. Finally, sensitivity analyses are presented which are constructed to test 
robustness of outcomes to modification of the claims data cohort. Further sensitivity 
analyses relate to the impact of a change of the age structure of the model cohort on the 
agreement of model and claims data outcomes. 
In chapter 4 results of the validation of the PCa-model are presented; first, results of the 
claims data analysis. Secondly, results of the additional model analyses conducted for this 
study are displayed. Input parameters as well as simulation outcomes of model and claims 
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data are compared; unadjusted and simulated results of the comparison are presented in 
tables and graphs. The impact of sensitivity analyses on outcomes is described, as well. 
Chapter 5 interprets and contrasts results presented here to published validation 
approaches. Strengths and limitations of claims data in respect to the research question are 
discussed. The practical implications of results for model validation but also application of 
the validation approach in industry is debated. Special focus lies on the critical assessment of 
the proposed validation approach. The applicability of the validation approach to 
administrative data from health care systems other than the German SHI and applicability to 
indications other than PCa are discussed.   
Chapter 6 contains concluding remarks and indicates areas requiring further research. 
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2 Example of use: localized prostate cancer 
2.1 Disease background 
2.1.1 Epidemiology and socioeconomic burden 
PCa is the second most common cancer in men worldwide and the most common in 
Germany, making it a major health concern (57, 58). Reported worldwide incidence rates 
vary widely, being highest in the regions of the United States (US) and Europe where 
prostate specific antigen (PSA) testing and subsequent biopsies have become widespread, 
leading to a continuous increase in incidence rates (59).   
PCa-specific mortality rates, on the other hand, are decreasing since the 1990s in Germany 
and other European countries (60). Today, 5-year relative survival rates are around 83% for 
men newly diagnosed with PCa (61). This is, in part, due to the fact that screening methods 
allow earlier tumor detection (62).  
 
Source: according to Luengo-Fernandez et al. 2013 (63) 
Figure 2-1: Health care costs of prostate cancer per person in European Union countries in 
2009, by health care service category 
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PCa is a diagnosis which occurs mostly in older men; mean age at diagnosis is 69 years (59). 
In the light of demographic change – it is estimated that around 34% of the population will 
be over 65 years of age in 2060 in Germany – a further increase in incidence of PCa is 
expected (64). In turn, the discrepancy between incidence and mortality rate will likely 
increase further. 
With the expected demographic change and increase in the incidence of PCa, the economic 
burden in Europe is also expected to increase significantly. Even today, annual health care 
spending due to PCa is substantial and accounts for €5.43 billion in the European Union (EU), 
with a high proportion of the health care costs occurring in the first year after diagnosis. 
Germany exhibits the highest PCa-related health care costs per person in the EU, mostly due 
to inpatient expenditures (Figure 2-1). The correlation between health care expenditure and 
cancer mortality is, however, unclear (63). A cross-country comparison of PCa incidence and 
mortality rates indicates that health outcome in Germany is slightly better than in other 
European countries (Figure 2-2) (59). 
                                        
Source: according to Robert-Koch-Institut et al. (2013) (59) 
Figure 2-2: Cross-country comparison of age-standardized prostate cancer incidence and 
prostate cancer-specific mortality rates (per 100,000), 2009/2010  
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2.1.2 Diagnosis and tumor classification 
The diagnosis of early stage PCa is usually suspected based on digital rectal examination 
(DRE) and PSA levels. PSA is a serum marker, with higher values indicating a higher 
probability of PCa (65). 
Confirmation of the diagnosis requires histopathological verification of the tumor, usually 
adenocarcinoma, in the prostate biopsy cores or operative specimens.  
T - Primary tumor 
TX   Primary tumor cannot be assessed 
T0   No evidence of primary tumor 
T1   Clinically inapparent tumor not palpable or visible by imaging 
 T1a Tumor incidental histological finding in 5% or less of tissue resected 
 T1b Tumor incidental histological finding in more than 5% of tissue resected 
 T1c Tumor identified by needle biopsy  
T2  Tumor confined within the prostate 
 T2a Tumor involves one half of one lobe or less 
 T2b Tumor involves more than half of one lobe, but not both lobes 
 T2c Tumor involves both lobes 
T3  Tumor extends through the prostatic capsule 
 T3a Extracapsular extension (unilateral or bilateral) including microscopic bladder 
neck involvement 
 T3b Tumor invades seminal vesicle(s) 
T4  Tumor is fixed or invades adjacent structures other than seminal vesicles: 
external sphincter, rectum, levator muscles, and/or pelvic wall 
N - Regional lymph nodes 
NX  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1  Regional lymph node metastasis 
M - Distant metastasis 
MX  Distant metastasis cannot be assessed 
M0  No distant metastasis 
M1  Distant metastasis 
 M1a Non-regional lymph node(s) 
 M1b Bone(s) 
 M1c Other site(s) 
Source: according to Sobin et al. 2009 (66) 
Table 2-1: Tumor Node Metastasis (TNM) classification of PCa 
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The standard diagnostic procedure is to use ultrasound to guide prostate biopsies and to 
administer oral antibiotics before the procedure to prevent an infection (65). Complications 
of prostate biopsy include hematuria and hematospermia as well as post-procedural 
infections. Reported rates of severe infections have increased due to the evolution of 
antibiotic resistant strains (67). 
Tumor grade is based on the pathology of prostate core biopsies or surgery specimens. The 
(modified) Gleason grading system, as defined by the 2005 consensus conference of the 
International Society of Urological Pathology, is used to grade prostatic adenocarcinoma. In 
the Gleason system, grades are based on the architectural pattern of the tumor (grade 1-5). 
The Gleason score is reported as the sum of the two most common grade patterns (score 2-
10) (68).  
Tumor stage describes the extent of the prostatic carcinoma. It is usually assessed by DRE 
and PSA testing and supplemented by bone scan or computed tomography (65, 69). It is 
standard in clinical trials and routine care to define tumor stage by the  Tumor Node 
Metastasis (TNM) classification proposed by the International Union Against Cancer (Table 
2-1) (66). ‘Localized PCa’ is present in stages T1-2 N0 M0, whereas ‘locally advanced PCa’ in 
stages T3-4 N0 M0. Stages N1 and M1 indicate ‘metastatic PCa’. 
Based on PSA level, Gleason score, and TNM stage, localized tumors are further categorized 
regarding the risk of recurrence (70): 
o Low-risk:   PSA ≤ 10 ng/ml and Gleason score ≤ 6 and T-stage 1/ 2a 
o Intermediate-risk:  PSA > 10 ng/ml - 20 ng/ml or Gleason score 7 or T-stage 2b 
o High-risk:   PSA > 20 ng/ml or Gleason score ≥ 8 or T-stage 2c 
Risk factors for PCa are still unclear; however there is a strong correlation with age and 
family history of PCa. Untreated prostate tumors are, generally, characterized by a slow 
natural progression where patients predominantly die of other causes than PCa (69). 
Detected tumors are often localized, clinically insignificant cancers, which do not require any 
treatment in their lifetime (Figure 2-3) (59, 71).  
In this light, early detection and screening programs for PCa are controversial among experts 
as they bear the risk of over-detection and, following that, overtreatment. A Cochrane 
review of five randomized controlled trials, representing more than 341,000 randomized 
men, could not show any PCa-specific survival benefit of screening (72). In Germany, no 
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population screening program for PCa based on PSA testing is recommended by health 
authorities; regular DREs are covered by SHI in line with PCa screening. However, if a patient 
wishes an early detection examination in form of PSA testing, this is covered by SHI as well 
(69).  
        
Source: according to Robert-Koch-Institut et al. 2013 (59) 
Figure 2-3: Distribution of tumor stage at diagnosis, Germany 2009/ 2010 
2.1.3 Treatment of localized prostate cancer 
Treatment of localized PCa can be divided into two groups: treatment strategies with a 
curative intention and conservative management (CM) strategies with deferred treatment.  
Standard curative treatment of localized PCa is radical prostatectomy (RP), which can be 
performed with a retropubic, perineal, or (robot-assisted) laparoscopic approach.  The entire 
prostate gland is removed between the urethra and bladder, and both seminal vesicles, 
along with sufficient surrounding tissue to obtain a negative margin, are removed (65). The 
aim of RP is eradication of disease, while preserving urinary continence and if possible 
erectile function (73). Still, post-operative urinary incontinence (IC) and erectile dysfunction 
(ED) are common complications following RP. Recent systematic reviews report mean 
continence rates of 80-97% with retropubic RP versus 89-100% with robot-assisted RP and 
mean potency rates of 26-63% versus 55-81%, respectively, 12 months after surgery (74, 75).   
Radiotherapy is an alternative to surgery for curative therapy of localized PCa. Definitive 
radiotherapy includes external-beam radiotherapy (EBRT) and brachytherapy. Intensity-
modulated radiotherapy, with or without image-guidance, is the gold standard for EBRT (65). 
Brachytherapy describes a therapy option where a radiation source is implanted via a 
transperineal approach (69). Complications of radiotherapy are late genitourinary (including 
IC) or gastrointestinal toxicity as well as ED (65, 76). Radiotherapy affects potency, however, 
to a lesser degree than retropubic RP: a meta-analysis from 2002 reports 12-month 
probability for maintaining erectile function of 55-76% after radiotherapy and 25-34% after 
RP (77). 
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Other curative therapies, with less evidence regarding outcomes, are not recommended in 
guidelines as primary treatment of localized PCa. These include proton beam therapy, 
cryosurgery, and high-intensity focused ultrasound therapy (65, 69). 
Data suggest that many men with localized PCa do not benefit from curative treatment in 
terms of survival, because tumor progression is so slow that no treatment is required (78). 
The CM strategies active surveillance (AS) and watchful waiting (WW) have been proposed 
as alternatives to curative treatment to reduce overtreatment and subsequent 
complications. It is estimated that about 45% of men with a PSA-detected PCa are 
candidates for CM (79).  
Based on published evidence, the German Association of Urology (Deutsche Gesellschaft für 
Urologie; DGU) and the European Association of Urology (EAU) define eligibility for AS 
strategy by the following criteria (69, 80, 81): 
o PSA-level ≤ 10 ng/ml 
o Gleason score ≤ 6 
o Tumor stage T1 and T2a 
o Life expectancy ≥ 10 years 
The recommended surveillance scheme consists of PSA testing, DRE, and regular biopsies 
(69). PSA tests and DRE should be performed every 3 months for the first 2 years, after that 
every 6 months if the PSA level is stable. The first biopsy is supposed to be taken 6 months 
after surveillance initiation and in the first 3 years, follow-up biopsies are taken every 12-18 
months. If tumor status is stable, further biopsies are performed every 3 years. Studies 
suggest, though, that in addition to complications described previously, regular biopsies 
might affect erectile function (82, 83). 
Curative treatment is initiated if the inclusion criteria described above are no longer met. 5 
to 10 percent of men under AS choose a curative treatment although tumor progression 
does not require it (84). 
If life expectancy is less than 10 years or co-morbidity does not allow any other form of PCa-
treatment, watchful waiting (WW) is suggested. This strategy has no standardized follow-up 
scheme and does not monitor tumor progression closely. Symptom-oriented, palliative 
therapy is initiated if disease progresses (69). 
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Comparative effectiveness of localized PCa treatment is usually reported as overall mortality, 
PCa-specific mortality, or health-related quality of life. At the time of literature search, only 
two RCTs report comparative effectiveness outcomes of localized PCa treatment: the 
Scandinavian SPCG-4 trial and the US-based PIVOT trial.  
The SPCG-4 trial randomly assigned 695 newly diagnosed, localized PCa cases to RP or WW. 
After a follow-up of 23 years, the SPCG-4 trial showed that RP was associated with a 
reduction of all-cause mortality compared to WW (relative risk (RR)=0.77, confidence 
interval (CI) [0.59;0.86], p<0.001). RP was also associated with a reduction in PCa-specific 
mortality (RR=0.56, CI [0.41;0.77], p=0.001) as well as development of distant metastases 
(RR=0.57, CI [0.44;0.75], p<0.001) and use of androgen-deprivation therapy (ADT) (RR=0.49, 
CI [0.39;0.60], p<0.001) (85). Health-related quality of life was better in the RP group than in 
the WW group, but lower in both cases compared to a general-population control. 
Reduction in quality of life is induced by ED and IC in case of RP, whereas men under WW 
are predominantly affected by symptoms of tumor progression (86). 
The PIVOT trial also randomized 731 men with localized PCa to RP or WW. After a median 
follow-up of 10 years the trial showed, contrary to SPCG-4, that RP did not significantly 
reduce all-cause mortality (hazard ratio (HR)=0.88, CI [0.71;1.08], p=0.22) or PCa-specific 
mortality (HR=0.63, CI [0.36;1.09], p=0.09) compared to WW (87). 
RCT evidence on comparative (cost-)effectiveness of RP, EBRT, brachytherapy, and AS is 
expected to be available when results of the ongoing ProtecT trial (United Kingdom; UK) and 
the German PREFERE trial are available (88, 89).  
Several observational studies report comparative effectiveness outcomes. In a study with 
about 28,000 localized PCa-cases, identified in the Surveillance, Epidemiology, and End 
Results (SEER) population-based cancer registry (US), non-curative therapies (AS, WW, TURP) 
are significantly associated with an increased risk of PCa-specific mortality compared to 
curative therapies (RP, EBRT, brachytherapy) (HR=1.05, CI [1.02;1.08], p<0.001) over a 2.5 
year study duration (90). First results of the German observational study, HAROW, indicate 
that after 2 years of follow-up, AS exhibits the highest tumor progression rate (31%) and 
EBRT the lowest (7%) compared to RP, ADT, and WW. All-cause and PCa-specific mortality 
have not been reported yet (91). Results of both studies, however, are limited in their 
validity due to a short follow-up and non-randomization. 
Example of use: localized prostate cancer  25 
 
 
In the CaPSURE-registry (US) health-related quality of life outcomes are shown for several 
localized PCa therapies (RP, EBRT, brachytherapy, ADT, WW/ AS). There is no significant 
difference in physical and mental health, assessed by the Medical Outcomes Studies Short 
Form-36 (SF-36), after 10 years of follow-up (92). Similarly, the PCOS study, a US-based 
registry including about 3,500 men newly diagnosed with PCa and treated with either RP or 
radiotherapy, found no significant differences between the groups regarding SF-36 results. 
(93). 
A meta-analysis examining curative treatment of low-risk PCa reports higher progression-
free survival rates for brachytherapy than RP and EBRT, which have comparable rates (94). 
The PRIAS study recruits men under AS worldwide and reports effectiveness outcomes, but 
does not compare these to any other PCa-specific treatments (95). 
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2.2 Cost studies 
One economic study reports disease-related resource use and costs for treatment of 
localized PCa based on RCT data – the SPCG-4 trial. After 12 years of follow-up, total mean 
costs per patient are significantly higher in the RP group than in the WW group with a 
difference of €6,123 (34%, p<0.01). This difference originates predominantly in the costs of 
the surgical procedure (96). A cost study based on CaPSURE registry data (US) also concludes 
that WW generates lowest annual disease-related costs over a period of 5 years compared 
to RP, EBRT, brachytherapy, cryotherapy, and ADT (97). Similar results are presented by both 
a cost study on data from the French network of cancer registries and a cost analysis based 
on SEER-Medicare linked data (98, 99). 
A cost study conducted with claims data from several US health insurance funds reports 
that, while costs of RP and EBRT are significantly higher than costs of CM in year 1 with 
additional $15,200 and $18,900 respectively, after year 2 no significant cost differences can 
be shown between treatment strategies (100). Only one cost analysis comparing in- and 
outpatient urologist reimbursement for AS to RP over a period of 10 years reports that costs 
of AS exceed costs of surgery after 4 years of follow-up (101). 
Cost analyses based on decision-analytic models present similar results to observational 
studies: A Markov model, comparing costs of RP, EBRT, brachytherapy, ADT, and AS, reports 
cost savings per patient of AS amounting to $16,039 (CI [16,039;16,042], p<0.001) after 5 
years and $9,944 (CI [9,941;9,948], p<0.001) after 10 years compared to immediate curative 
therapy. EBRT in combination with ADT has the highest costs after 5 and 10 years follow-up 
(102). Eldefrawy et al. (2013) and Corcoran et al. (2010) also report that cumulative costs of 
AS are lowest, even though AS has higher follow-up costs than curative treatment (103, 104). 
When considering effectiveness and costs, the Markov model by Koerber et al. (2014) shows 
that AS is the dominant strategy compared to RP with 0.04 additional QALYs and a cost 
reduction of €6,883 per patient. Considering only life years gained without quality 
adjustment as outcome measure, RP is more effective with an ICER of €96,420/life year 
gained (105). In contrast, a Markov model based on SPCG-4 trial data reports that RP has 
higher costs but also higher QALY outcomes than AS (106). 
The decision analytic model by Hayes et al. (2013) directly compares AS and WW in a cost-
effectiveness analysis. It shows that WW is cost-saving compared to AS by $15,374 with a 
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quality-adjusted life expectancy gain of 2 months. AS becomes as effective as WW if less 
than 63% of men progress to curative treatment in their lifetime (78). 
A cost-effectiveness analysis of RP compared to radiotherapy shows that  surgical methods 
are – in terms of QALYs – significantly more effective and less expensive than radiotherapy 
strategies for the treatment of low-risk PCa (107). 
Overall, evidence suggests that CM strategies, especially WW, save health care costs which 
arise due to unnecessary curative therapy and treatment of its adverse effects, and 
additionally achieve better quality of life outcomes. Most studies base cost analysis on US 
reimbursement values, though, which are not representative for European health care 
systems, mainly due to cost differences between public and private health care systems 
(108).  
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2.3 Validated model 
A lifetime Markov model by Koerber et al. (2014), comparing the cost-utility of AS and RP for 
a cohort of men newly diagnosed with low-risk PCa, was chosen as the basis for validation 
(105). The PCa-model was selected from 3 decision models on different indications, 
developed at Helmholtz Zentrum München, because it features structural assumptions and 
data sources that are commonly used in decision-analytic modeling. Also, it includes 
resource use and cost parameters from a wide range of health care service categories. These 
characteristics make the model suitable for a validation example; results of the validation 
can be transferred to other indications. Also, the decision model is highly relevant for 
German SHI funds because PCa has a high (socioeconomic) burden of disease in Germany 
and treatment incurs substantial costs at the expense of SHI funds. Thus, external validation 
based on SHI claims data seems suitable for this model, as it is assumed that a patient cohort 
and outcomes relevant for SHI funds can be analyzed in SHI claims data. 
In the decision model by Koerber et al. (2014) men enter the model at the age of 65 years 
and are assumed to have a life expectancy greater than 15 years as well as no severe co-
morbidities, including benign prostate hyperplasia (BPH).  
Utility is measured in QALYs; direct medical costs, including out-of-pocket payments, from a 
broad range of health care service categories (in- and outpatient care, pharmaceuticals, 
assistive technologies, physiotherapy) are considered. The model adopts the perspective of 
the SHI scheme insurant population as recommended by the German Institute for Quality 
and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im 
Gesundheitswesen; IQWiG). 
Figure 2-4 provides an overview of the Markov model. In case of local recurrence after RP, 
EBRT is the primary treatment option. In case of local progression under AS, RP is the 
standard treatment for men < 72 years of age and EBRT for older men, respectively. 
Metastatic disease is treated by ADT and in case of refractory disease by chemotherapy. For 
bone metastasis treatment with zoledronic acid and radiation therapy is assumed.  
Adverse effects of RP include short- and long-term ED, IC, and a combination of both. After 
EBRT men may, additionally, develop bowel problems which include abdominal pain, 
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bloating, and diarrhea. Regular biopsies performed under AS may lead to urosepsis requiring 
hospitalization. PCa-specific or other-cause death may occur in any state. 
The model is implemented in Treeage Pro 2013. 
 
Source: Koerber et al. 2014 (105) 
Figure 2-4: Structure of the validated model by Koerber et al.  
A variety of data sources provide evidence for the model. Treatment pathways are based on 
recommendations from DGU (109). Health state specific utility rates are derived from 
published literature (110-112). In the absence of suitable evidence, it is assumed that AS 
exhibits the same utility as life after curative treatment without side effects. Comparative 
PCa-specific mortality is based on evidence from the SPCG-4 trial comparing RP and WW 
(113). To adapt results to AS strategy it is assumed that half the treatment effect of RP is 
maintained compared to AS. The transition probability of developing metastases under AS is 
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also adapted from the SPCG-4 trial. All other transition probabilities are derived from a 
meta-analysis comparing AS and RP (114).   
Resource utilization is based on treatment guidelines and estimation by clinical experts 
(109). Outpatient unit costs are based on values of the physicians’ fee catalogue and 
inpatient costs on DRG weights from the German DRG catalogue (115, 116). Pharmaceutical 
prices are extracted from the German formulary (117); unit costs of assistive technologies 
and physiotherapy are based on market prices provided by health care providers. 
Parts of the model were validated during model building. Face validity of the model 
structure and of major assumptions was screened within the modeling team and by a clinical 
expert. This resulted in adaptation of the model regarding development and treatment 
probabilities of adverse effects as well as assumptions on resource utilization.  Results of the 
model were cross validated with results of two existing decision-analytic models comparing 
effectiveness and one cost-utility analysis comparing effectiveness and costs of AS and RP. 
All studies report that more QALYs are generated under AS than with initial RP (78, 112, 
118). The QALY advantage of AS reported by Koerber et al. (2014) is, however, smaller 
because an age related decline in quality of life is considered. Regarding costs, Hayes et al. 
(2013) also found that AS is a cost-saving strategy. The probability of PCa-specific death was 
externally validated with data from the PIVOT RCT, which did not change strategy rankings 
(87).  
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3 Methods 
3.1 Validation approach 
Based on the theoretical literature and published examples of external model validation, 
described in chapter 1.2, an approach to the external validation of decision-analytic models 
based on claims data is proposed which highlights critical steps in the validation process. The 
individual validation steps include the selection of 1) validation level, 2) claims dataset, study 
design, and patient cohort, 3) relevant health states and health technologies, 4) statistical 
methods for claims data analysis, 5) changes to the decision model, 6) comparison between 
model and claims data, and 7) sensitivity analyses. 
Implementation of this step-wise approach is described exemplarily for the validation of the 
Markov model on treatment of localized PCa by Koerber et al. (2014) based on claims data 
from a German SHI fund in the following chapters 3.2 to 3.8. 
Step 1: Validation level 
The decision on the validation level depends on the uncertainty present in the validated 
model. An external validation based on claims data is useful for decision-analytic models, 
which present substantial parameter uncertainty regarding resource use, probability of 
utilization, or costs. Efficacy or quality of life outcome measures are difficult to validate 
based on claims data, because clinical information is typically very limited and diagnostic 
codes are, in most cases, not sufficient to describe severity of disease and quality of life. 
Effectiveness measures concerning utilization of health technologies, such as number of 
hospital episodes, on the other hand, are validly represented in claims data. 
To compare outcomes of the decision model and the external data source two general 
approaches are possible. In the first approach, the decision model simulates cohort 
characteristics and study design of the external data source, which is usually a published RCT 
or observational study; the decision model is then run with the parameter values extracted 
from the external data source. In the second approach, outcomes are independently 
estimated in the external data source and the decision model; parameter values of the 
external data source are not incorporated in the decision model.   
External validation can be applied to input parameters fed into the model (such as resource 
use and unit costs) and simulation outcomes generated by the model (such as probability of 
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utilization and accumulated costs over the study period). Validation of input parameters is 
useful to explain differences between model simulation outcomes and claims data 
outcomes. Differences in outcome might be due to differing input parameters, the model 
calculation itself, or a combination of both. 
Step 2: Claims dataset, study design, and patient cohort 
The most important criterion for the selection of the claims dataset used for the validation is 
that study design, assumptions, and patient cohort of the decision model can be replicated 
as closely as possible. To achieve this, the insurance fund(s) providing the dataset should be 
located in a health-care system with similar treatment pathways and reimbursement 
arrangements as assumed in the decision model.  
The indication or treatment of interest should be present in the claims dataset in a 
population large enough to estimate valid outcomes. Furthermore, characteristics of the 
model cohort (such as age structure, co-morbidity, or socioeconomic status) should be found 
in the claims dataset. The coding of diagnoses and procedures in the claims dataset should 
make it possible to select a cohort according to the inclusion criteria of the model (e.g. 
distinction between localized and metastatic PCa-disease).  
It should also be ensured that the claims dataset allows a long enough follow-up of patients 
to be comparable to the whole model span or, at least, parts of it representing relevant 
disease stages. A unique identification number is necessary to merge claims from different 
health care service categories and years on an individual insurant level.  
Step 3: Relevant health technologies and costs  
To identify within the claims data set the utilization and costs of treatment strategies 
compared in the model, a definition of disease-related health technologies is necessary. This 
definition can be set more or less closely to the decision model’s definition of disease-
related health care utilization. It can either strictly follow the definition used in the decision 
model by, for example, using the same procedure codes on which the identification of 
disease-related health technology utilization is based. Or a wider definition of codes may be 
applied, if no information on the definition of disease-related health care utilization is 
provided for the model or codes used in the model do not exist in claims data.  
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Codes for calculation might also be defined irrespective of the model’s definition of disease-
related technology utilization. In addition to parameter uncertainty, structural uncertainty 
regarding the definition of resource utilization in the model is addressed in this case. 
An alternative approach to estimation of disease-related technology utilization is an excess 
approach. In this case, all health care utilization incurred at the health insurance fund, 
irrespective of the relevance for the treatment of interest, is summarized and compared 
between treatment alternatives. The absolute value of resource utilization and 
corresponding costs of a treatment strategy estimated via an excess approach has no 
informative value and, thus, only validation of incremental outcomes of the decision model 
is possible.  
Resource use and costs may be defined by codes of inpatient (OPS) and outpatient 
procedures (EBM), pharmaceuticals (PZN), assistive technologies, and physiotherapeutic 
procedures in SHI claims data. For the identification of health technologies relevant for the 
treatment of adverse effects of PCa-treatment, identification of health states that describe 
these adverse effects may be necessary. Health states are usually defined as diagnostic ICD-
codes in claims data. 
Depending on the perspective of the decision model only costs incurred by the SHI fund or 
costs additionally including co-payments of insured individuals (SHI scheme insured 
community) can be considered in SHI claims data analysis. 
Step 4: Statistical methods for claims data analysis  
For one, statistical methods are used to reflect cohort assumptions of the decision model in 
the claims data analysis. An important assumption in decision models is that treatment 
groups are equal in their baseline characteristics, such as age, gender, and co-morbidity. In 
claims data analysis, as in all observational studies, no randomization into treatment groups 
is possible which would ensure equal distribution of baseline characteristics. Statistical 
methods are available to mitigate selection bias due to non-randomization in claims data 
analysis. These include matching techniques, adjustment in regression analysis, and 
stratified analysis. 
Secondly, standard statistical methods for health economic evaluation should be applied for 
cost analysis in claims data. These include methods which take the skewed distribution of 
cost data into account, such as generalized linear models with a gamma-distribution and log-
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link as well as two-part models. Application of the recycled predictions method is useful to 
estimate an absolute cost difference between treatment strategies which is needed for the 
comparison with model outcomes.  
Step 5: Changes to decision model  
Depending on the characteristics of the claims data set, it might be necessary to change 
model assumptions to make comparison with claims data possible – provided that access to 
the model is granted. This may include adaptation of the runtime of the model to the study 
period of the claims data analysis.  
In addition, it might be difficult to replicate the age structure of the model cohort in claims 
data. Especially, if the model assumes that patients all have the same age at treatment 
initiation, treatment groups in claims data can become very small. Adaptation of the age 
structure of the model to the claims data cohort is necessary in this case.  
Additional analyses may be necessary, because decision models usually only report total 
costs per strategy. For the validation, however, it might also be interesting to simulate 
probability of utilization and costs of single treatments; differing total costs in claims data 
and model may be explained by differing utilization and costs of single treatments. 
Furthermore, it is of interest to analyze the validity of model simulations in different health 
care service categories, such as inpatient and outpatient care.  
The model structure should not be changed to conduct additional analyses; the aim of 
external validation is the comparison of input parameters and simulation outcomes of the 
model as it was originally designed with an external data source, and not the adaptation of 
the model structure to the external data source. 
Step 6: Comparison between model and claims data  
Absolute costs of each treatment strategy might be compared between model and claims 
data. Alternatively, incremental costs as estimated by claims data and model are compared, 
which is of greater importance for the decision maker. 
As a first step, resource use and costs estimated in claims data analysis may be compared 
with outcomes generated by a microsimulation of the decision model; in microsimulation a 
cohort including the same number of patients as in claims data analysis is simulated in the 
decision model. Microsimulation pictures variability due to the alternative pathways through 
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the decision model and is similar to the population variability of outcome in the claims data 
analysis. Descriptive (mean, standard deviation, median, interquartile range) and graphical 
presentation is useful to show distribution and variability of results. 
In a second step, uncertainty of parameters in claims data and model analysis may be 
considered. Outcomes generated by regression analysis and bootstrapping of claims data are 
compared with outcomes of Monte Carlo simulation of the decision model. Overlapping of 
simulated outcomes can be shown graphically. Additionally, the hypothesis that simulated 
incremental costs of the model are equal to observed incremental costs of claims data 
analysis may be tested by statistical methods described in chapter 1.2.3. 
Step 7: Sensitivity analyses 
Sensitivity analyses are useful to explain differences between model and claims data. For 
one, sensitivity analyses can address changes to the claims data cohort. This might include 
changes to the inclusion criteria in the claims data cohort to replicate the assumptions of the 
decision model more closely.  
Apart from sensitivity analyses conducted with claims data, it might be useful to vary model 
assumptions as well, for example the age structure in the decision model, to assess whether 
differences in outcome are due to differing assumptions in model and claims data analysis. 
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3.2 Validation level 
As described above, the first step in the external validation of the PCa-model by Koerber et 
al. (2014) is the selection of the validation level. 
In this study an external validation of resource use, probability of utilization, and cost 
parameters is chosen, because in the decision model these parameters are mainly based on 
expert estimates and national reimbursement catalogues, which are afflicted by a high 
degree of uncertainty. Effectiveness parameters, on the other hand, are based on high 
quality evidence from clinical trials and should be more valid. Also, effectiveness outcome is 
measured in QALYs in the PCa-model, which cannot be assessed in the AOK claims data set 
because clinical information is not included in sufficient detail to establish quality of life. 
Resource use and costs are independently calculated in AOK claims data analysis and PCa 
model; outcomes of AOK claims analysis are not incorporated in the model. Instead PCa 
model’s cohort and study design are replicated in AOK claims data analysis to achieve 
comparable results. 
Furthermore, both input parameters (resource use and unit costs) and simulated outcomes 
(probability of utilization and per capita costs) of the PCa-model are validated in this study.  
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3.3 Claims data set, study design, and patient cohort 
3.3.1 Dataset 
In the second step of the validation approach, a suitable claims dataset for the validation of 
the PCa decision model is selected. A dataset from a German SHI fund is useful for the 
validation of a decision model set in a German health care context with the perspective of 
the SHI scheme insurant population. The insurant population expected to be treated for 
localized PCa was estimated in the study planning phase, based on prevalence data for the 
general German population for 2 SHI funds, AOK Baden-Württemberg and Deutsche 
Angestellten-Krankenkasse (DAK). It was decided to perform model validation with data 
from AOK Baden-Württemberg, as the PCa-cohort was estimated to be larger than in DAK 
data (estimated number of incident PCa-cases AOK Baden-Württemberg: 3,817, DAK: 929). 
AOK Baden-Württemberg is the largest SHI fund in the south-western German federal state 
of Baden-Württemberg with about 3.9 million insured individuals in 2014, which 
corresponds to 43% of the SHI scheme insured community in Baden-Württemberg. About 
44% of insured individuals are mandatory members, 25% of insured individuals are retired, 
the remaining individuals are either family members or voluntarily insured at AOK Baden-
Württemberg (119).  
Historically, AOK insurance funds provided health insurance for blue collar workers with 
lower educational status and income compared to other SHI funds. This insurant structure of 
AOK still exists in alleviated form (Figure 3-1), although insured individuals are free to choose 
an insurance fund since the 1990s in Germany (120). Implications of insurant structure on 
generalizability of results are discussed in chapter 5.3.2. 
AOK Baden-Württemberg provided access to data on all claims incurred between 2008 and 
2011 in the following health care service categories: inpatient and outpatient care, 
pharmaceuticals, assistive technologies, physiotherapy, outpatient rehabilitation, work 
incapacity and sick pay. Additionally, basic insurant information such as age, gender, 
nationality, insurance status, date of death or date of termination of membership are 
provided. Earlier claims were not accessible because of a change in the database system 
which does not allow merging data before and after 2008. Claims after 2011 were not 
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available yet, at the time of data selection in July 2012. All claims are available on a patient 
level and can be merged by a personalized insurant identification number. Co-payments to 
medical services covered by SHI are included in the dataset, whereas patients’ out-of-pocket 
payments for other services are not.  
German data protection laws were considered during extraction and analysis of data and 
AOK Baden-Württemberg approved of the intended use of the data. An ethics committee 
was consulted regarding this study; ethics approval is not necessary as identification of 
individual persons is not possible in the dataset (see Appendix B for ethics committee 
statement).  
 
Source: according to Gesundheitsmonitor 2008 (120) 
Figure 3-1: Social status of insured individuals (%), by insurance 
fund 
3.3.2 Study design 
In the second step of the validation approach, also a study design for the AOK claims data is 
selected, which replicates model assumptions. Due to the secondary nature of the 
underlying data source, an observational study design is given where no form of 
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randomization into treatment groups or intervention is possible. To replicate the modeling 
approach a prospective, longitudinal study design is chosen, where a cohort of men 
diagnosed with early-stage PCa is followed from the point of treatment initiation (121). As in 
the model, the alternative treatment options RP and AS are considered. 4 consecutive years 
of AOK claims allows a maximum follow-up of 2.5 years, which in turn allows validation of 
the first 10 3-month cycles of the decision model by Koerber et al. (2014). Thus, only the part 
of the decision model representing treatment of localized disease is considered for 
validation, because follow-up is too short to include individuals with disease progression. 
The probability for disease progression in the first years after initial treatment, assumed in 
the model is extremely small (< 1%). 
 
Figure 3-2: Study timeline (AOK) 
The study period covers 4 years, from January 1st 2008 to December 31st 2011, and is 
divided into 3 sections (Figure 3-2):  
1) The 6-month pre-observation period ranges from January 1st 2008 to June 30th 2008. In 
order to allow for co-morbidity adjustment of outcomes, this period before initial 
treatment is created as a basis to calculate a Charlson Co-morbidity Score (CCS) for each 
insured individual. CCS is calculated based on diagnoses coded before initial treatment, 
to ensure that diseases, which are complications of the treatment of interest (AS or RP), 
are not considered in the calculation (122). 
2) In the 12-month observation period from July 1st 2008 to June 30th 2009 PCa-cases are 
identified and categorized into treatment groups.  An observation period of 12 months is 
chosen, on the one hand, to identify a sufficient number of men treated with AS or RP to 
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analyze resource utilization and costs. On the other hand, the risk is decreased that men 
waiting for radical treatment are falsely classified as AS-patients.  
3) The cohort is followed-up for a period of 2.5 years (follow-up period). In case of RP, 
follow-up time starts individually after the date of the initial surgery for each insured 
individual. Individuals under AS are followed for a fixed period from July 1st 2009 to 
December 31st 2011. One reason for this is that the starting point of AS cannot be 
established in the chosen cohort, because the time of initial PCa-diagnosis – when AS 
usually starts – cannot be identified in the AOK data. Thus, an artificial starting point for 
AS has to be created, which is the beginning of the observation period (July 1st 2008). 
Secondly, follow-up is not intended to start with the onset of AS. This is due to the 
selection process in this study, where men under AS have to be surveyed for at least 12-
months (the observation period) to be included in the cohort. Thus, men under AS who 
die in this period are not considered for analysis. In the RP-group, on the other hand, a 
single event (the RP surgery) at some point in the observation period determines 
inclusion in the cohort, which in turn possibly includes men dying in this period. In 
conclusion, individuals under AS have, by definition of the selection strategy, a lower 
probability to die in the observation period. To account for this bias, follow-up of AS is 
offset by 12 months. 
3.3.3 Cohort selection 
Furthermore, in step 2 of the validation process the cohort is selected in AOK claims data. 
In a first step all insured individuals with an ICD-coding of ‘C61 - Malignant neoplasm of 
prostate’ in any health care sector were identified in the complete claims of AOK Baden-
Württemberg of the year 2008. For the identified individuals claims from all health care 
sectors of the years 2008 to 2011 were extracted. To comply with data protection laws the 
baseline dataset was pseudonymized, which includes deletion of all information that allows 
identification of individuals (insurant identification number, name, address, date of birth) 
and creation of a pseudonymized identification number for each individual. Furthermore, 
information which allows identification of single health care providers (e.g. hospitals, 
physicians, pharmacies) was deleted from the baseline dataset. The pseudonymized baseline 
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dataset was transferred from AOK Baden-Württemberg to Helmholtz Zentrum München for 
data analysis. 
 
Figure 3-3: Cohort selection (AOK) 
The first step of the cohort selection process (Figure 3-3) is to identify individuals with a 
validated PCa-diagnosis in the 12-month observation period. PCa diagnosis is validated in 
three ways. First, only men are considered with at least one inpatient or at least two 
outpatient diagnostic codes of C61 in different quarters of the observation period. Secondly, 
only main diagnostic codes determined at discharge are used in case of inpatient diagnoses, 
because these codes are most valid for hospital care (123). Thirdly, only codes with the 
additional diagnostic certainty code ‘secured’ (G, gesicherte Diagnose) are considered for 
outpatient diagnoses. In German outpatient care tentative diagnoses are usually added the 
code ’V: tentative diagnosis’ or ‘A: exclusion of the coded diagnosis’. When the diagnosis is 
clarified, the code ‘G: secured diagnosis’ is added. If the disease is cured the additional code 
is changed to ‘Z: state after disease’. To include only patients in the cohort with a current 
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diagnosis of C61, all diagnoses with additional codes other than G are not considered for 
cohort selection. By applying the criterion of at least two diagnostic codes, consideration of 
tentative diagnoses is further minimized (124). 25,367 insured individuals apply to these 
criteria.  
After exclusion of individuals not constantly enrolled in the study period or with female 
gender coding, the dataset includes 25,293 individuals. 
Diagnostic ICD-10 GM codes, inpatient (OPS) and outpatient procedure (EBM) codes, as well 
as pharmaceutical prescriptions (coded by ATC codes) are used to define inclusion and 
exclusion criteria for cohort selection (Table 3-1 and Table 3-2).  
Diagnosis ICD-10 GM 
Metastases C77, C78, C79 
Other cancer C00-C14, C15-C26, C30- C39, C40-C41, C43-C44, C45-C49, C50, C51-C58, C60, 
C62, C63, C64-C68, C69-C72, C73- C75, C76, C80, C81-C96 
PCa C61 
Table 3-1: Diagnostic codes for cohort selection (AOK) 
Procedure 
Inpatient  
(OPS) 
Outpatient  
(EBM) 
Pharmaceuticals 
(ATC) 
PSA test - 32351 - 
Prostate biopsy - 26341 - 
RP 5-604 36276, 36277, 36287 - 
EBRT 8-520, 8-521, 8-522, 8-523  25321 - 
Chemotherapy 8-54 86512, 86514 - 
Brachytherapy 8-524, 8-525 25333 - 
Orchiectomy 5-622 - - 
ADT - - L02AE 
Table 3-2: Procedure codes for cohort selection (AOK) 
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Following the definition of AS in the PCa-model by Koerber et al., which is based on the 
surveillance recommendation of the DGU of 2014 (69), AS is defined by EBM codes of at 
least two PSA tests and at least one prostate biopsy during the observation period. DREs, 
which are recommended in a 3 monthly frequency, cannot be identified in SHI data, because 
these are covered by the urologic insurant lump sum and are, thus, not coded separately. To 
limit the cohort to early stage PCa, men with diagnoses on metastatic or any other kind of 
cancer disease are excluded. Additionally, patients undergoing any form of PCa-specific 
therapy other than AS (RP, EBRT, brachytherapy, chemotherapy, orchiectomy, and ADT) in 
the observation period are excluded to avoid misclassification of individuals waiting for 
radical treatment as AS cases. The inclusion and exclusion criteria mentioned above apply to 
the observation period only. In the follow-up period, men in the AS-group do not have to be 
surveyed as closely as defined in the observation period. They may move on to any other 
form of PCa-specific therapy or develop metastatic disease, as assumed in the decision 
model.  
RP is defined by inpatient as well as outpatient procedure codes on open, laparoscopic, or 
robotic-assisted radical prostatectomy. Individuals with a diagnosis of metastatic or any 
other kind of cancer than PCa in the observation period are excluded. Other forms of PCa-
specific treatment may be performed in addition to RP in the observation period, because 
inclusion criteria are not supposed to be so strict that treatment practice is not reflected in 
the cohort.  
Application of above mentioned inclusion and exclusion criteria creates a cohort consisting 
of 124 individuals in the AS-group and 910 in the RP-group. 
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3.4 Relevant health technologies and costs 
In step 3 of the validation, health technologies and corresponding costs relevant for PCa-
treatment are defined. In this study, two different approaches for the definition of relevant 
health technologies in the AOK claims data are explored: an excess approach and a disease-
related approach.  
3.4.1 Excess approach 
The excess analysis is a pragmatic approach to external validation of decision models based 
on claims data; it gets by with few assumptions in addition to study design and cohort 
selection in claims data, because no definition of disease-specific health care utilization is 
necessary. All health care utilization and corresponding costs accruing in the follow-up 
period are considered for analysis. When comparability of the AS- and the RP-group 
regarding patients’ baseline characteristics can be ensured (e.g. by statistical methods 
described in the following), the difference in outcome is solely attributable to the difference 
in initial PCa-treatment (52).  
However, the absolute outcome values (resource use or costs) of treatment strategies have 
no informative value for validation, because disease-specific costs which are considered in 
the PCa model are not represented. With the excess approach only the validation of 
incremental outcome measures is possible. All the same, excess analysis is useful for the 
validation, because it indicates whether AOK claims data estimate similar incremental 
outcomes as the decision model and whether it is reasonable to go to the time and effort to 
analyze AOK claims data on a disease-related basis. 
3.4.2 Disease-related approach 
In disease-related analysis only resource use of health technologies and corresponding costs 
that are relevant for the treatment of localized PCa are considered. Disease-related analysis 
allows validation of absolute values of resource use and costs of the 2 treatment strategies 
in addition to incremental outcomes. Also, comparison of utilization and costs of single 
health technologies is possible; by that not only total outcome of the model is validated but 
also outcome in different health care service categories. The validity of model outcomes 
might, for example, differ in in- and outpatient care. Furthermore, disease-related analysis 
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helps to explain difference in total outcome between model and claims data by difference in 
outcome of single health technology utilization or difference in unit cost estimates. 
Health care utilization and corresponding costs of PCa-treatment are identified in the 2.5 
years of follow-up after initial treatment. Only treatment relevant for localized PCa is 
considered, whereas treatment of metastatic disease and palliative therapy are not 
considered; only the part of the PCa-model is validated which evaluates treatment of 
localized PCa. 
The definition of health technologies relevant for the treatment of localized PCa in claims 
data analysis follows the definition of the model very closely. Whenever codes for the 
calculation of resource use and costs are explicitly mentioned in the model, these codes are 
used in claims data analysis as well. In in- and outpatient care DRG and EBM codes are 
reported in the model to identify health technology utilization. In all other health care 
service categories no specific codes of health technologies are available; in these cases 
corresponding codes are identified in claims data in consultation with the modeling team. 
Costs are reported in Euro (€) as in the decision model. Discounting of costs is not necessary 
due to the short study period. 
Some deviations from the definition of disease-related costs in the PCa-model are necessary; 
mainly to ensure that only PCa-relevant treatment is included in claims data analysis. For 
one, inpatient treatment is defined by OPS codes in claims analysis rather than by DRGs as in 
the PCa-model, because OPS codes are more specific. For example, to identify the utilization 
and costs of prostatectomy without complications, a search for a combination of DRG M01B 
‘Major procedure at the male pelvic organs without complications’ and OPS 5-604 ‘Radical 
prostatectomy’ is used. The DRG code alone is too unspecific to identify RP in claims data, 
because code M01B is also used to bill procedures other than RP.   
Secondly, in claims data analysis criteria for the temporal link between ICD, EBM, or OPS 
codes are defined. For example, treatment of IC by a general practitioner (GP) is defined by 
generic EBM codes, because no specific codes for treatment of IC are available. Thus, to 
consider this treatment relevant for the analysis a diagnosis of IC in the same quarter is 
required.  
46  Methods 
 
 
Table 3-3 lists all health technologies that are assumed to be relevant for the treatment of 
localized PCa by health care service category; corresponding codes for the selection of 
disease-related technologies in claims data are provided. 
Regarding costs of the identified health technologies, generally, all costs are considered that 
are relevant for the perspective of the SHI scheme insured community, which includes 
reimbursement by the insurance fund as well as out-of-pocket payments of insured 
individuals. DRG codes for hospital episodes, in which relevant procedures are performed, 
are used to estimate costs in claims data analysis. In case of outpatient treatment, costs are 
usually reported on a quarterly case basis by EBM codes. To make costs comparable to the 
decision model, costs of single EBM procedures are considered and not the costs of the 
whole case.  
To allow direct comparison of utilization probability and costs estimated in claims data with 
outcomes of the decision model, single health technologies are summarized in cost groups 
according to the cost groups defined in the decision model (Table 3-4). 
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Cost group model Treatment claims data 
ED Outpatient treatment ED (urologist) 
Outpatient treatment ED (GP) 
Pharmaceutical PDE5 inhibitors 
Vacuum pump, rings 
IC Outpatient treatment IC (urologist) 
Outpatient treatment IC (GP) 
Incontinence aids 
Physiotherapy pelvic floor 
RP w/o complications Prostatectomy w/ o complications 
AS PSA testing and biopsies (urologist) 
Antibiotics before prostate biopsy 
EBRT EBRT after AS (radiotherapist) 
Urosepsis Inpatient treatment urosepsis 
TURP Transurethral prostate resection for BPH 
Surgery IC Artificial urethral sphincter surgery  
Sling surgery  
Surgery ED Penis prosthesis surgery 
RP with complications Prostatectomy with complications 
BPH  Alpha blockers, 5α-reductase inhibitors 
Stricture  Inpatient treatment stricture 
Monitoring RP Follow-up RP: PSA testing  (urologist) 
Total Sum of all cost groups  
Table 3-4: Assignment of health technologies to cost groups  
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3.5 Statistical methods for claims data analysis 
In step 4 of the validation of the PCa-model, statistical methods are selected which allow 
estimation of outcomes in AOK claims data comparable to outcomes of the decision model. 
These include matching of individuals in the AS- and the RP-group as well as regression 
analysis of effect and cost outcomes.  
3.5.1 Matching 
Matching is a statistical technique which, in part, corrects the treatment selection bias 
induced by non-randomization. Each AS-subject is individually paired with a RP-subject for 
variables that might confuse the comparison. Matching is only useful, though, for variables 
that are strongly related to both the treatment and outcome of interest (28). Age is chosen 
as the matching variable because it is strongly related to the treatment decision; AS is 
recommended for patients with a life expectancy greater than 10 years. Regarding health 
outcome, rates of ED and IC as well as corresponding health care utilization are also 
correlated with age (125). Furthermore, matching of the claims data cohort makes the 
comparison with the decision model more valid, because the model assumes that there is no 
difference in age distribution between treatment groups. 
Treatment groups are matched by +/- 2 years of age and in a ratio of 1 AS-subject to 2 RP-
subjects to account for the relatively smaller group of patients under AS. Especially for rare 
events the strength of the study can be increased by having more RP-subjects than AS-
subjects in the cohort (28). 
After matching, the AS-group includes 107 individuals and the RP-group 214, respectively. 
All statistical analyses are performed with the software package SAS, version 9.3. 
3.5.2 Descriptive analysis of patient characteristics 
Patients’ age and CCS as well as prevalence of ED, IC, and benign prostate hyperplasia (BPH) 
are calculated at baseline before and after matching. For calculation of CCS the co-morbidity 
group ‘cancer’ is set to 0, because diseases other than PCa are of interest for adjustment.  
Definition of ED, IC, and BPH on the basis of ICD-10 GM codes is shown in tTable 3-5. 
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Diagnoses coded in in- and outpatient care are used and the same criteria for validity of 
diagnoses as for cohort selection are applied: only inpatient discharge diagnoses and 
outpatient diagnoses with the additional coding ‘secured’ are used. 
Comparison of patient characteristics in the 2 treatment groups allows estimation of the 
usefulness and performance of matching. Furthermore, characteristics of the claims data 
cohort and model cohort are compared based on the descriptive analysis.  
Diagnosis ICD-10 GM 
Benign prostate hyperplasia (BPH) N40 
Erectile dysfunction (ED) N48.4, F52.2 
Urinary incontinence (IC) N39.3, N39.4, R32, F98.0 
Table 3-5: Diagnostic codes for effect analysis (AOK) 
3.5.3 Effect analysis 
Rates of short- and long-term (continuous diagnosis > 90 days after initial treatment) ED and 
IC as well as rates of BPH are estimated per treatment group in the follow-up period of 2.5 
years. These rates are relevant for the analysis of disease-related resource utilization: 
identification of individuals with complications of PCa treatment is required for the 
identification of utilization of PCa-relevant health technologies, which are not specifically 
coded as treatment of PCa and are not linked to diagnostic information in claims data (e.g. 
outpatient treatment of IC).  
‘Incident’ ED and IC diagnoses are considered in effect analysis, which means that only 
subjects are included which do not have a diagnosis of IC or ED before the initial RP surgery 
or, in case of AS, before the beginning of follow-up. This is important for the comparison 
with the model, because it is assumed in the model that individuals in both treatment 
groups do not have ED, IC, or BPH before initial treatment. The definition of diagnostic codes 
for effect analysis has been described previously (Table 3-5). 
To address bias in complication rates due to difference in baseline co-morbidity in the 2 
treatment groups, a logistic regression model is used to adjust for CCS. Logistic regression 
models are suitable to predict the proportion of subjects with a complication of interest by 
using a logit transformation. The odds ratio of an individual having the complication is 
predicted by the logistic regression model (28). 
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The method of recycled predictions is applied to estimate mean complication rates per 
treatment strategy (the probability of having the complication of interest) in addition to 
odds ratios. Recycled predictions can impart the scale of group differences better than the 
regression coefficients alone, because probabilities are easier to interpret than odds ratios 
(126). To achieve this, the predicted probabilities of complications are at first estimated 
under the assumption that all individuals in the sample are treated with RP and all other 
variables remain the same; secondly, the predicted probabilities of complications are 
estimated assuming all in the sample are under AS and, again, all other variables remain the 
same. Finally, the averages of these two predicted probabilities are compared and a new 
estimate of the difference between AS and RP is produced (126).  
95% CIs of mean complication rates per treatment strategy and incremental complication 
rates are calculated via non-parametric bootstrapping with 1,000 replications. The 
bootstrapping method refers to a random sampling technique with replacement. The mean 
costs are calculated for each re-sample and these re-samples make up the empirical 
estimate of the distribution of mean costs. This allows calculation of accuracy measures – 
such as confidence limits – for estimated means, in samples with small observation numbers, 
where the assumption of asymptotic normality of the estimator is questionable. To calculate 
95% CIs, the 2.5 and 97.5 percentile values of the sampled distribution are taken to 
represent the endpoints of the interval (127, 128). P-values indicating significant differences 
in complication rates between treatment strategies are estimated via bootstrap hypothesis 
testing; p-values less or equal to 0.05 are considered statistically significant.      
3.5.4 Excess analysis of resource use and costs 
For the excess analysis all health care utilization incurred at the SHI fund are considered, 
irrespective of the relevance for PCa treatment. As in the decision model, utilization of 
inpatient and outpatient care, pharmaceuticals, physiotherapy, and assistive technologies 
are considered and corresponding costs are summarized to total costs per treatment 
strategy. The difference in costs reflects the excess costs of AS compared to RP, assuming 
that matching and adjustment in regression analysis control for treatment selection bias and 
the difference is solely attributable to the treatment. 
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All direct medical costs are considered that are relevant for the perspective of the SHI 
scheme insured community, according to the German SGB V (§ 35b (1) SGBV) (129). Co-
morbidity adjusted costs are estimated per treatment group by a generalized linear model 
(GLM) with a gamma distribution and log link to account for the typically skewed distribution 
of cost data. To individuals with zero costs a small amount of €1 is assigned to include them 
in the analysis (130). When individuals with zero costs account for more than 10% of the 
cohort a two-part model is used: at first the probability of health care expenditure is 
predicted with a logistic regression model. In a second step costs are estimated by a GLM, as 
described previously, conditional for nonzero costs. To derive unconditional per capita costs 
the probability of expenditure is multiplied by the predicted conditional costs (131). The 
GLM reports the cost difference between the AS- and the RP-strategy as a percentage. 
Additionally, recycled predictions method is applied to estimate absolute values of mean 
costs per strategy and difference in costs (52, 126). All costs are rounded to the nearest € 
and inflation is not considered due to the short study period. 
For per capita costs and difference in costs 95%-CIs are calculated via a non-parametric 
bootstrap approach based on 1,000 replications, by taking the 2.5 and 97.5 percentile values 
to represent the endpoints (128, 132). P-values indicating significant differences in costs are 
estimated via bootstrap hypothesis testing; p-values less or equal to 0.05 are considered 
statistically significant. The CCS is included in the regression models as a continuous variable 
to adjust for difference in co-morbidity in the treatment strategies (133, 134). To additionally 
estimate the influence of ED and IC on treatment costs, complication is included in the 
regression models as a binary variable. Extended models, with an interaction between 
treatment strategy and CCS, do not improve model fit. 
3.5.5 Disease-related analysis of resource use and costs 
In disease-related analysis 4 different outcome measures are estimated: resource use of 
treated individuals, unit costs, probability of technology utilization, and per capita costs 
accumulated during follow-up. 
o Resource use is reported as the quantity of utilization per person of a single health 
care technology, averaged over all individuals treated with the technology of interest, 
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in the follow-up period. RP surgery is, for example, expected to be performed only 
once per person, whereas treatment with EBRT involves several radiation sessions.  
o Unit costs describe the mean costs of one procedure, hospital episode, or 
pharmaceutical description.  
o The absolute and relative number (probability) of individuals in the cohort utilizing a 
health technology is reported for single treatments and for cost groups.  
o Per capita costs accumulating during follow-up are reported for cost groups with 
standard deviation (STD) as well as median and interquartile range, to give an 
indication of the distribution of costs. Especially in cost groups where a small number 
of individuals causes costs, extremely skewed distribution of costs is possible; in that 
case STD has no meaningful interpretation (28). 
To adjust costs for difference in co-morbidity a GLM with a gamma distribution and log-link 
including CCS as a continuous variable is used, as described in chapter 3.5.4. Non-parametric 
bootstrapping with 1,000 replications is applied to estimate 95% CIs for mean costs of all 
cost groups. P-values indicating significant differences in costs between treatment strategies 
are estimated via bootstrap hypothesis testing; p-values less or equal to 0.05 are considered 
statistically significant. A random number seed is set during bootstrapping to allow 
replication of results and to generate comparable results for all cost groups. 
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3.6 Changes to the decision model 
In step 5 of the validation approach, model assumptions are changed and additional analyses 
are conducted to make the comparison of outcomes with claims data more valid. Such a 
change of assumptions is possible because access to the PCa-model in Treeage is granted by 
Koerber et al. (2014). 
3.6.1 Adaptation of model assumptions to claims data 
Change of model assumptions includes adaptation of the runtime of the decision model to 
the follow-up period of the AOK claims data analysis of 2.5 years, which corresponds to 10 
cycles of 3 months in the model. A longer follow-up or lifetime perspective could not be 
created in the claims data analysis, because claims are only available for a period of 4 
consecutive years. 
Also, it is not possible to replicate the age structure of the model cohort in claims data. If 
inclusion in the claims data cohort requires that all patients are 65 years of age at treatment 
initiation as in the decision model, treatment groups in claims data would become very 
small. Adaptation of the age structure of the model to the claims data cohort is necessary; 
consequently the mean age of the SHI cohort at treatment initiation (70 years) is assumed in 
the PCa-model. Mortality rates and the probability to be treated with either RP or EBRT 
following AS – which are the only relevant age-dependent probabilities – are adapted 
accordingly in the PCa-model. 
Furthermore, discounting of costs is not performed in claims data analysis, due to the short 
period of follow-up. The PCa-model as published by Koerber et al. (2014) assumes an annual 
discount rate of 3% for costs, which is set to 0% for the purpose of this validation. 
3.6.2 Additional analyses 
For the model validation it is interesting to compare not only the probability and costs of all 
PCa-relevant health care utilization combined but also of single treatments. It is especially 
interesting in this study whether the validity of model parameters is higher in inpatient care, 
where OPS codes allow specific identification of procedures and DRG reimbursement 
provides valid cost estimates, than, for example, in outpatient care where coding of 
procedures via EBM codes is less specific.  
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To simulate health care utilization and costs of single treatments in the decision model, 
additional analyses are necessary, because the decision model reports only total costs per 
treatment arm. Such additional analyses are conducted without changing the model 
structure. 
To compare utilization probability in the decision model with utilization probability 
estimated in claims data analysis, a microsimulation (also referred to as first-order Monte 
Carlo simulation) is performed in Treeage Pro 2013. Microsimulation pictures variability due 
to the alternative pathways of simulated individuals through the decision model and is 
similar to the population variability of outcome in the claims data (135). A cohort of 321 men 
in each treatment arm is followed individually through the model.  
To estimate probability of utilization per cost group the microsimulation is run for each cost 
group separately, each with all other cost groups set to 0. The utilization probability of 
health technologies in each cost group is estimated as the number of individuals with costs > 
0.  
Averaging the costs over the 321 patients gives the overall estimate of the mean costs in 
each treatment arm. Simulated outcomes are exported from Treeage and imported to SAS 
for analysis of mean costs, STD, median, and interquartile range.  
To account for parameter uncertainty in cost estimates probabilistic sensitivity analysis, 
using second-order Monte Carlo simulation with 1,000 replications, is performed in Treeage 
Pro 2013 for each cost group and total costs individually. Monte Carlo simulation allows 
simultaneously sampling from each cost parameter distribution (135). Because the precision 
of simulation point estimates depends on the number of replications, a consistent approach 
with 1,000 replications is used for model and claims data (22). Monte Carlo simulation 
samples are exported to SAS for cost analysis. Mean costs estimated by each sample are 
averaged over all 1,000 replications to calculate 95% CIs by taking the 2.5 and 97.5 
percentile values to represent the endpoints of the interval (135). 
A random number seed is set in Monte Carlo simulation as well as in microsimulation to 
ensure that the results are replicable from one run to the next and to make outcomes 
comparable between cost groups.  
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3.7 Comparison between model and claims data 
In step 6 of the validation of the PCa-model based on AOK claims data, methods for the 
comparison of model and claims data outcomes are selected. 
3.7.1 Input parameters: resource use and unit costs 
Input parameters of resource use and unit costs included in the decision model are 
compared with resource use and unit costs estimated in claims data analysis. Difference in 
resource use and unit costs is described, whereas treatments which have a presumably high 
influence on total difference are especially highlighted. 
3.7.2 Simulation outcome: probability of utilization and per capita costs 
The probability of utilization of health technologies summarized in cost groups is displayed 
graphically in form of bar charts, directly comparing outcomes of unadjusted claims data 
analysis and microsimulation of the PCa-model. Bar charts are created for the AS- and the 
RP-group separately. Differences between outcomes are described, focusing on results that 
are most relevant to explain differences in total costs. 
Unadjusted mean costs estimated in claims data analysis are compared with outcomes 
predicted by microsimulation of the decision model. Distribution of costs is displayed 
graphically in form of histograms contrasting estimates of claims data analysis with 
estimates of model microsimulation. Histograms show results separately for the AS- and the 
RP-group. 
To test agreement between estimates of AOK dataset and model simulation statistically, the 
difference between incremental costs estimated in adjusted claims data analysis and 
incremental costs predicted by the decision model in Monte Carlo simulation is calculated; 
the difference in incremental costs is calculated for all cost groups and for total costs. 
Calculation of differences is based on the 1,000 sampled means of bootstrapping and Monte 
Carlo simulation, accordingly; each bootstrapped sample is assigned to a sample generated 
in Monte Carlo simulation and the difference in costs is then calculated for each of this 
samples. Based on the 1,000 sampled differences a mean difference is estimated.  
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Bootstrapping of outcomes generates a non-parametric distribution of the cost differences. 
For mean differences 95% CIs are calculated, taking the 2.5 and 97.5 percentile values of the 
bootstrap generated distribution to represent the endpoints.   
The research hypothesis in this study is that the model is able to simulate outcomes 
observed in claims data. Consequently, incremental costs estimated in claims data are 
expected to be the same as incremental costs simulated in the model; the difference in 
incremental costs of model and claims data is expected to be 0. In hypothesis testing the 
research hypothesis – which one wants to prove – is usually expressed in the alternative 
hypothesis (H1). The null hypothesis (H0) is the negation of the research hypothesis. H0 is 
rejected, if the probability that the observed data could have been obtained with H0 being 
true (the p-value), is lower than a predefined significance level, usually 0.05. Following this, 
H0 would have to state in this study that the cost difference between claims data and model 
is unequal; a test of this hypothesis is, however, statistically not possible (28). 
Consequently, the test is formulated in the usual manner:  
H0: incremental costsAOK = incremental costsmodel 
H1: incremental costsAOK ≠ incremental costsmodel 
H0 is tested based on simulated samples via bootstrap hypothesis testing (136). When 0 is 
included in the 95% CI or the p-value is greater than 0.05, H0 is not neglected, but this does 
not mean that H0 is accepted or proven. P-values lower than 0.05 indicate a rejection of H0 
and a significant difference between incremental costs of claims data and model (28, 29).  
Additionally to hypothesis testing, the distribution of sampled incremental costs of claims 
data analysis and decision model is displayed in histograms for all cost groups and total 
costs. An overlapping of the histograms indicates an agreement between incremental costs 
of claims data analysis and Monte Carlo simulation.  
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3.8 Sensitivity analyses 
In step 7 of the validation approach, sensitivity analyses are selected which test the 
influence of claims data and model assumptions on outcome. 
3.8.1 Incident PCa-cases in claims data analysis 
In a sensitivity analysis only incident PCa cases are included to estimate the influence of the 
cohort selection on difference in costs in claims data analysis. A more valid comparison with 
the PCa-model is possible, because the model assumes incidence of disease. Incidence of 
disease might be especially relevant in the AS group; it can be ensured that only individuals 
are included in the analysis who started AS in the observation period. That way, time under 
treatment is the same in the RP- and the AS-group.  
 
Figure 3-4: Cohort selection of incident PCa-cases (AOK) 
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Individuals with no coding of PCa, identified by ICD-10 GM code C61, in the pre-observation 
period and at least one inpatient or two outpatient diagnostic codes in the observation 
period are considered for analysis. After exclusion of individuals with incorrect gender 
coding or dropping-out during the study period, 5,720 individuals remain in the incident 
cohort (Figure 3-4). Applying the inclusion and exclusion criteria for treatment groups 
described previously, leaves 88 individuals in the AS-group and 776 individuals in the RP-
group. After matching for age in a ratio of 1:2, the AS-group consists of 64 individuals and 
the RP-group of 128, respectively. 
Excess costs and total disease-related costs are estimated in claims data analysis per 
treatment strategy. Adjusted and bootstrapped incremental costs are compared with 
outcomes of Monte Carlo simulation of the PCa-model as described in the base analysis 
(chapter 3.7). 
3.8.2 Age distribution in the decision model 
In a second sensitivity analysis the influence of the age at treatment initiation, assumed in 
the decision model cohort, on agreement with claims data estimates is tested. As described 
previously, age at treatment initiation and corresponding age-dependent variables are 
changed to 70 years of age, to reflect the mean age of the claims data cohort. Age in the 
claims data cohort, however, varies: the 2.5 percentile is 51 years of age and the 97.5 
percentile is 79, respectively.  
Age at treatment initiation is relevant in the model because treatment with RP or EBRT after 
AS depends on age; before 72 years of age RP is recommended, older men are treated with 
EBRT. If every individual in the base case model starts AS at the age of 70 and follow-up 
continues for 2.5 years, the probability of being treated with EBRT in follow-up is much 
lower than being treated with RP. As EBRT is less costly than RP, costs of AS-strategy may be 
overestimated. 
To test this influence on agreement of claims data and model, the PCa-model is once run 
with an age at treatment initiation of 51 years and once with 79 years, respectively. In the 
first analysis, with mean age of 51 years of age, no patient in the AS-group is assumed to be 
treated with EBRT and in the second analysis, with 79 years of age, all patients in the AS-
group are treated with EBRT in follow-up. 
Difference in incremental costs is compared as described in base analysis (chapter 3.7).   
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4 Results 
4.1 Patient cohort in claims data 
Results of the baseline characteristics of the patient cohort in the claims data set, which is 
defined in step 2 of the validation approach, are presented in the following. 
Mean age at baseline (before the initial treatment) in the claims data cohort is 69 years (STD 
6.80) in the RP-group and 70 years (STD 7.13) in the AS-group after matching (Table 4-1). 
Mean CCS, representing co-morbidity in the cohort, is 0.11 in the RP-group and 0.19 in the 
AS-group. STD of 0.63 in both treatment strategies is comparatively high, which indicates a 
skewed distribution of co-morbidity in the treatment groups; a small number of men have 
high co-morbidity scores compared to the remaining individuals in the cohort with CCS of 0.  
Prevalence of ED and IC is slightly higher in the RP-group than in the AS-group at baseline 
after matching (ED: 0.11 vs. 0.05, IC: 0.05 vs. 0.03). Prevalence of BPH is considerably higher 
in the RP-group with 0.77 as opposed to 0.68 in the AS-group. From a medical point of view, 
this result can be explained by the fact that men suffering from symptoms of BPH tend to 
surgery for treatment of PCa because BPH is cured by RP as well.  
 Before matching  After matching 
 RP AS  RP AS 
Total (n) 910 124  214 107 
Age (m, STD) 66 (6.64) 70 (8.31)  69 (6.80) 70 (7.13) 
CCS (m, STD) 0.13 (0.71) 0.19 (0.62)  0.11 (0.63) 0.19 (0.63) 
ED (n, p) 79 (0.09) 5 (0.04)  24 (0.11) 5 (0.05) 
IC (n, p) 18 (0.02) 5 (0.04)  10 (0.05) 3 (0.03) 
BPH (n, p) 511 (0.56) 83 (0.67)  164 (0.77) 73 (0.68) 
m = mean, n = number, p = proportion 
Table 4-1: Baseline characteristics before and after matching (AOK) 
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Comparison of baseline results before and after matching shows that the RP-group gets 
older and, in line with that, prevalence rates of ED and IC as well as BPH increase. The AS-
group, on the other hand, features predominantly the same baseline characteristics before 
and after matching. Overall, the RP- and the AS-group show a satisfactory concordance in 
baseline characteristics after matching, except for co-morbidity. To account for different co-
morbidity structures in the treatment groups, CCS is adjusted for in regression models in the 
following. 
In the claims data cohort 14 out of 321 individuals (4.4%) die during follow-up; the mortality 
rate is, however, greater in the AS-group (7.5%) than in the RP-group (2.8%).  
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4.2 Effect analysis of claims data 
Results of the analysis of complication rates, described in step 4 of the validation approach, 
are presented in the following. 
Unadjusted analysis of short- and long-term ED and IC rates in the follow-up period indicates 
that after RP complication rates are higher than after AS (0.48 vs. 0.12) (Table 4-2). However, 
the number of individuals with some complications is extremely small in the AS-group. For 
example, only 2 individuals suffer from a combination of ED and IC. Even though this result is 
valid from a medical point of view, it is difficult to estimate valid costs based on such a small 
number of individuals; this should be considered when assessing the validity of disease-
related cost estimates in the AS-group. 
Complication RP (n=214) AS (n=107) 
ED < 90 d  31 (0.15) 6 (0.06) 
ED > 90 d  26 (0.12) 6 (0.06) 
IC < 90 d  92 (0.43) 9 (0.08) 
IC > 90 d 70 (0.33) 9 (0.08) 
ED & IC < 90 d  20 (0.09) 2 (0.02) 
ED & IC > 90 d 16 (0.08) 2 (0.02) 
Total (ED or IC or both) 103 (0.48) 13 (0.12) 
d = days, n = number  
Table 4-2: Mean complication rates – unadjusted (AOK) 
Complication 
                 RP                AS 
      m      95% CI        m       95% CI 
ED < 90 d 0.15 0.10 to 0.20  0.06 0.02 to 0.10 
ED > 90 d  0.12 0.08 to 0.17  0.06 0.02 to 0.10 
IC < 90 d 0.44 0.36 to 0.50  0.08 0.04 to 0.14 
IC > 90 d 0.33 0.27 to 0.40  0.08 0.04 to 0.14 
ED & IC < 90 d 0.10 0.06 to 0.14  0.02 0.00 to 0.05 
ED & IC > 90 d 0.08 0.08 to 0.12  0.02 0.00 to 0.05 
Total (ED or IC or both) 0.49 0.42 to 0.55  0.12 0.07 to 0.19 
CI = confidence interval, d=days, m = mean 
Table 4-3: Mean complication rates – adjusted (AOK) 
64  Results 
 
 
When adjusting for co-morbidity, results change very little. After RP rates of short- and long-
term IC (0.44, CI [0.36; 0.50] and 0.30, CI [0.27; 0.40]) as well as short-term ED (0.15, CI 
[0.10; 0.20]) are significantly higher than in the AS-group (0.08, CI [0.04; 0.14]; 0.08, CI [0.04; 
0.14]; 0.06, CI [0.02; 0.10]) (Table 4-3). Overall, total complication rates are significantly 
lower in the AS-group than in the RP-group (-0.37, CI [-0.45; -0.27], p< 0.0001) (Table 4-4). 
Complication 
                       AS - RP 
   m      95% CI  p-value 
ED < 90 d  -0.09 -0.15 to -0.02      0.008 
ED > 90 d  -0.07 -0.13 to 0.00      0.050 
IC < 90 d  -0.35 -0.43 to -0.26 < 0.0001 
IC > 90 d -0.25 -0.33 to -0.16 < 0.0001 
ED & IC < 90 d  -0.08 -0.12 to -0.03 < 0.0001 
ED & IC > 90 d -0.06 -0.10 to -0.02      0.006 
Total (ED or IC or both) -0.37 -0.45 to -0.27 < 0.0001 
CI = confidence interval, m = mean 
Table 4-4: Difference in complications rates – adjusted (AOK)  
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4.3 Excess analysis of claims data 
In the following results of the excess analysis of claims data are presented; definition of 
health technologies relevant for excess analysis and statistical methods for analysis are 
described in steps 3 and 4 of the validation approach.  
 
Figure 4-1: Per capita total costs (€), by treatment strategy and health care service 
category – unadjusted (AOK) 
 RP (n=214) AS (n=107) AS - RP
Inpatient   10,964 5,227  -5,737
Outpatient 3,668  2,750 -918
Pharmaceuticals 2,774  3,321  547
Physical therapy 331  271  -60
Assistive technologies 281  139  -142
Total costs  18,018  11,708  -6,310
Table 4-5: Per capita total and excess costs (€), by treatment strategy and 
health care service category – unadjusted (AOK) 
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Figure 4-1 shows unadjusted per capita costs for the two treatment strategies grouped by 
inpatient and outpatient treatment, pharmaceuticals, physiotherapy, and assistive 
technologies. AS incurs lower mean costs than RP in all health care service categories, except 
in case of pharmaceutical prescriptions (Table 4-5). 
Co-morbidity adjusted analysis confirms unadjusted excess cost analysis (Table 4-6 and Table 
4-7). Total costs of AS (€11,933, CI [9,430; 14,554]) are significantly lower than total costs of 
RP (€18,544, CI [16,867; 20,660]) by €-6,611 (CI [-9,734; -3,547], p<0.0001).  
Comparison of adjusted costs in single health care service categories displays that AS has 
significantly lower mean inpatient (€-5,845, CI [-7,632; -3,895], p<0.0001) and outpatient 
costs (€-961, CI [-1,622; -361], p=0.002) as well as costs for assistive technologies (€-141, CI [-
230; -50], p=0.006) than RP.  
Inclusion of complication as a binary variable into the regression models does not change 
cost differences between treatment strategies. Concerning total costs there seems to be no 
significant cost difference between individuals with and without complications. In case of 
assistive technologies a 30% increase in costs for individuals with complications is estimated 
(p=0.018). 
 RP AS 
    m              95% CI       m        95% CI 
Inpatient  11,123    10,157 to 12,308 5,278  3,718 to 6,977 
Outpatient 3,751     3,342 to 4,276 2,790  2,360 to 3,295 
Pharmaceuticals  2,893     2,267 to 3,776 3,480     2,718 to 4,490 
Physical therapy  346     236 to 491 288  182 to 428 
Assistive technologies  281     223 to 343 140     83 to 212 
Total costs  18,544     16,867 to 20,660 11,933     9,430 to 14,554 
m = mean 
Table 4-6: Per capita total costs (€), by treatment strategy and health care service 
category – adjusted (AOK) 
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                          AS - RP  
 m              95% CI     p-value
Inpatient  -5845        -7,632 to -3,895 < 0.0001
Outpatient -961    -1,622 to -361 0.002
Pharmaceuticals  587         -556 to 1,718 0.274
Physical therapy  -58      -214 to 114 0.460
Assistive technologies  -141      -230 to -50 0.006
Total costs  -6,611 -9,734 to -3,547 < 0.0001
Table 4-7: Excess costs (€), by health care service category – adjusted (AOK) 
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4.4 Disease-related analysis of claims data 
Results of disease-related analysis are presented in the following; disease-related health 
care utilization and methods for disease-related analysis are described in steps 3 and 4 of 
the validation approach. 
4.4.1 Resource use and unit costs 
The average quantity of resource use of treated individuals in the follow-up period and unit 
costs of disease-related health technologies are compared for the RP- and the AS-group in 
Table 4-8. 
When a health technology is not utilized in one of the treatment groups, no resource use 
and unit costs can be estimated in claims data analysis. For example, no unit costs can be 
estimated for EBRT as primary treatment in the RP-group because radiation after surgery is 
performed in case of disease progression and not as primary treatment of localized PCa.  
Inpatient treatment is predominantly utilized once; outpatient treatment is utilized several 
times. Follow-up after RP surgery by an urologist is performed about 2.5 times more on 
individuals in the RP-group (8.62) than on individuals in the AS-group treated with RP (3.50). 
This could, however, be due to a shorter period of follow-up after RP in the AS-group; follow-
up is overall limited to 2.5 years after the initial treatment. Resource use of remaining health 
technologies is comparable between treatment groups, if the health technology is utilized at 
all. 
Highest unit costs are estimated for RP surgery with complications (€10,141), artificial 
urethral sphincter surgery (€11,732), and penis prosthesis surgery (€7,586). However, all of 
these surgeries are performed in a small number of patients (number of treated individuals: 
41, 1, and 1, respectively) and each in only one of the two treatment groups; thus, unit cost 
estimates may not be representative for the cohort (Table A-1 appendix). 
If a health technology is utilized, unit costs are comparable between treatment groups. Small 
differences between the AS- and the RP-group in unit costs may arise because of annually 
varying reimbursement rates. In case of inpatient treatment, different length of stay or 
additional reimbursement, of for example intensive care, can explain small differences, as 
well. 
Results  69 
 
 
Treatment               Resource use p.p.              Unit costs (€) 
  RP AS RP AS
Inpatient     
Prostatectomy w/ o complications 1.00 1.00 6,417 6,295
Prostatectomy with complications 1.00 0.00 10,141 0
Treatment stricture (RP) 1.10 1.00 4,298 4,824
Penis prosthesis (ED) 1.00 0.00 7,586 0
Artificial urethral sphincter (IC) 0.00 1.00 0 11,732
Sling surgery (IC) 1.00 0.00 5,865 0
Treatment urosepsis (AS) 1.00 1.00 2,015 2,002
Transurethral prostate resection for BPH 0.00 1.10 0 4,715
Outpatient     
Follow-up RP: PSA testing  (urologist) 8.62 3.50 25 23
Treatment ED (urologist) 6.00 7.75 19 19
Treatment ED (GP) 4.75 6.20 35 36
Treatment IC (urologist) 6.24 9.14 20 19
Treatment IC (GP) 5.54 5.80 35 36
EBRT after AS (radiotherapist) 0.00 1.82 0 1,380
AS: PSA testing and biopsies (urologist) 0.00 7.36 0 44
Pharmaceuticals     
Antibiotics before prostate biopsy 0.00 1.12 0 16
α-blockers, 5α-reductase inhibitors (BPH) 0.00 5.93 0 47
PDE5 inhibitors (ED) 1.00 0.00 23 0
Assistive technologies     
Vacuum pump, rings (ED) 1.00 1.00 205 198
Incontinence aids (IC) 6.11 8.25 39 29
Physiotherapy     
Physiotherapy pelvic floor (IC) 22.52 17.00 14 14
Table 4-8: Resource use and unit costs of single health technologies (AOK) 
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4.4.2 Probability of utilization and per capita costs 
4.4.2.1 Unadjusted analysis 
The health technology with the highest utilization in the RP-group is the RP surgery itself 
(80% without complications, 20% with complications) and follow-up after surgery by an 
urologist (72%). In the AS-group highest utilization is found for PSA testing and biopsies 
(100%), which constitute the surveillance scheme (Table A-1 appendix). 
Utilization of remaining health technologies is low (< 10%) in both treatment groups, except 
for outpatient treatment of IC and use of incontinence aids in the RP-group with about 26% 
and 21%, respectively. Utilization of pharmaceuticals to treat symptoms of BPH is around 
50% in the AS-group.  
Low utilization, which corresponds to a low number of observations, influences validity of 
estimates of per capita costs; estimates based on a very low number of observations may 
not be representative of the whole cohort. Artificial urethral sphincter surgery, for example, 
is utilized by one individual in the AS-group only; estimated mean costs of treated individuals 
are extremely high with €11,732, which is about 2 times higher than the DRG (L04C, ca. 
€5,650) usually claimed for this procedure. 
The relation of cost group utilization corresponds to utilization of single health technologies, 
described above. The cost group ‘total’ comprises utilization of any of the listed cost groups. 
A utilization of 100% in both treatment groups indicates that every individual in the cohort is 
utilizing at least one of the health technologies in the follow-up period. Figure 4-2 shows the 
probability of utilization, categorized in cost groups as defined in the decision model, for the 
RP- and the AS-group. 
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Figure 4-2: Probability of utilization (%), by treatment strategy and cost group - unadjusted 
(AOK) 
Summarizing health technologies in cost groups mitigates the problem of small numbers of 
observations to a certain degree. Especially, the integration of health technologies for the 
treatment of ED and IC in corresponding cost groups, allows estimation of per capita costs 
based on larger numbers of observations (RP: 33 and 95 individuals, AS: 7 and 10 individuals) 
(Table A-2 appendix). 
Highest unadjusted per capita costs are found for RP surgery without complications in the 
RP-group (€5,067, STD €2,741) (Table A-2 appendix). A median of €6,335 and interquartile 
range of €1,424 show a relatively even distribution of surgery costs in the RP-group. Costs of 
RP surgery in the AS-group, on the other hand, accumulate to €235 per person. STD (€1,207), 
median (€0) and interquartile range (€0) show an extremely skewed distribution of surgery 
costs in the AS-group, where a small number of individuals incurs high costs. This cost 
distribution can be found in almost all cost groups, except for per capita costs of surveillance 
in the AS-group (€88, STD €40) and follow-up after surgery in the RP-group (€133, STD €101). 
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Total per capita costs amount to €7,711 (STD €3,511, median €6,990, interquartile range 
€1,771) in the RP-group and €1,658 (STD €4,142, median €250, interquartile range €703) in 
the AS-group, respectively.  
When comparing per capita costs between treatment groups in unadjusted analysis, it is 
shown that in 8 out of 13 cost groups the AS-group has lower costs, indicated by the minus 
sign (Table 4-9). The largest incremental costs are found for RP surgery without 
complications (€-4,832, STD 2,346). TURP and EBRT are by €685 and €258, respectively, 
more costly in the AS-group than in the RP-group. High STDs in both cost groups (€1,843 and 
€477) indicate extremely skewed distributions of incremental costs. 
In total, unadjusted per capita costs in the AS-group are by €6,054 (STD 3,733) lower than in 
the RP-group. 
Cost group  Incremental costs AS vs. RP (€) 
                          m                     STD 
ED -20 13
IC -132 334
RP w/o complications -4,832 2,346
AS 88 23
EBRT 258 477
Urosepsis -10 306
TURP 685 1,843
Surgery IC 55 825
Surgery ED -36 424
RP with complications -1,943 3,624
BPH 138 135
Stricture -176 1,231
Monitoring RP -131 83
Total -6,054 3,733
m= mean 
Table 4-9: Disease-related, per capita incremental costs (€), 
by cost group – unadjusted (AOK) 
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4.4.2.2 Adjusted, bootstrapped analysis 
When adjusting for co-morbidity in the regression model, highest per capita costs are found 
for RP surgery without complications (€5,051, CI [4,682; 5,400]) in the RP-group (Table 4-10). 
RP with complications incurs costs of €1,986 (CI [1,384; 2,655]) per person in the RP-group. 
In the AS-group highest per capita costs accumulate for the treatment of BPH with TURP 
(€771, CI [187; 1,792]); however, the wide 95% CI indicates substantial uncertainty regarding 
the cost estimate. Total costs amount to €7,861 (CI [7,314; 8,765]) in the RP-group and 
€1,601 (CI [928; 2,406]) in the AS-group, respectively. 
Cost group 
Costs p.p (€) 
                   RP    AS 
m       95% CI m   95% CI 
ED 39      26 to 55   20    5 to 39   
IC 172      127 to 223   40    8 to 82   
RP w/o complications 5,051      4,682 to 5,400   246    60 to 507   
AS 0      0 to 0  88  81 to 97   
EBRT 0      0 to 0  271   119 to 469   
Urosepsis 50       14 to 96   42    13 to 103   
TURP 0      0 to 0  771      187 to 1,792  
Surgery IC 69        15 to 149   178   110 to 358   
Surgery ED 83        68 to 143   0  0 to 0  
RP with complications 1,986      1,384 to 2,655   0  0 to 0  
BPH  0     0 to 0  140     97 to 188   
Stricture  223        70 to 443   69     34 to 170   
Monitoring RP 133      119 to 146   2   1 to 5   
Total 7,861      7,314 to 8,765   1,601      928 to 2,406  
m=mean 
Table 4-10: Disease-related, per capita costs (€), by cost group – adjusted (AOK) 
Adjusted incremental cost analysis shows that in the AS-group per capita costs of RP surgery 
without complications are by €4,805 (CI [-5,227; -4,359], p<0.0001) significantly lower than 
in the RP-group (Table 4-11). Costs of IC treatment (€-133, CI [-194; -71], p<0.0001) and 
monitoring after RP surgery (€-131, CI [-144; -117], p<0.0001] are also significantly lower in 
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the AS-group. In the remaining cost groups either no significant cost differences are found, 
or 95% CIs and p-values could not be estimated by the regression model, because in one of 
the treatment groups all individuals have costs of 0.  
In total, adjusted per capita costs in the AS-group are estimated to be by €6,260 (CI [-7,417; -
5,205], p<0.0001) significantly lower than in the RP-group. 
Cost group 
Incremental costs (€) AS vs. RP 
m    95% CI p-value
ED -19   -42 to 3     0.088
IC -133    -194 to -71  < 0.0001
RP w/o complications -4,805      -5,227 to -4,359   < 0.0001
AS 88 - -
EBRT 271 - -
Urosepsis -8     -64 to 63   0.606
TURP 771 - -
Surgery IC 106        -28 to 313   0.962
Surgery ED -34 - -
RP with complications -1,986 - -
BPH  140 - -
Stricture  -154   -389 to 24   0.060
Monitoring RP -131     -144 to -117   < 0.0001
Total -6,260      -7,417 to -5,205   < 0.0001
m=mean  
Table 4-11: Disease-related, per capita incremental costs (€), by cost 
group – adjusted (AOK) 
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4.5 Changes to decision model 
Results of changes to the decision model’s assumptions and additional analyses conducted 
with the model described in step 5 of the validation approach are presented in the following. 
4.5.1 Input parameters: resource use and unit costs 
Treatment Resource use p.p.         Unit costs (€) 
Inpatient  
Prostatectomy w/ o complications 1.00 6,886
Prostatectomy with complications 1.00 9,559
Treatment stricture (RP) 1.00 2,010
Penis prosthesis (ED) 1.00 8,452
Artificial urethral sphincter (IC) 1.00 6,394
Sling surgery (IC) 1.00 3,677
Treatment urosepsis (AS) 1.00 3,075
Transurethral prostate resection for BPH 1.00 3,037
Outpatient 
Follow-up RP: PSA testing  (urologist) 10.00 37
Treatment ED (urologist) 2.50 32
Treatment ED (GP) 5.00 54
Treatment IC (urologist) 2.50 32
Treatment IC (GP) 5.00 53
EBRT after AS (radiotherapist) 1.00 4,742
AS: PSA testing and biopsies (urologist) 9.00 55
Pharmaceuticals 
Antibiotics before prostate biopsy 2.50 8
Alpha blockers, 5α-reductase inhibitors (BPH) 16.25 108
PDE5 inhibitors (ED) 21.88 114
Assistive technologies 
Vacuum pump, rings (ED) 10.00 319
Incontinence aids (IC) - 39
Physiotherapy 
Physiotherapy pelvic floor (IC) 30.00 15
Table 4-12: Resource use and unit costs of single health technologies (PCa-model) 
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Same input parameters of resource use and unit costs are included in the decision model for 
the AS- and the RP-group. 
Resource use – incorporated in the model from published literature and expert interviews – 
is adapted to 10 cycles, corresponding to 2.5 years of follow-up. It shows that inpatient 
treatments are utilized once on average (Table 4-12). The largest quantity of utilization, in 
terms of number of treatments, is assumed for physiotherapy (30 treatments). 
Highest unit costs are assumed in the model for RP surgery with and without complications 
(€9,559 and €6,886) and penis prosthesis surgery (€8,452). Inpatient unit costs are, 
generally, considerably higher than unit costs of technologies in the remaining health care 
service categories.  
4.5.2 Simulation outcome: probability of utilization and per capita costs 
4.5.2.1 Microsimulation 
 
Figure 4-3: Probability of utilization (%), by treatment strategy and cost group - 
microsimulation (PCa-model) 
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Figure 4-3 shows the probability of utilization, categorized in cost groups of the PCa-model, 
for the RP- and the AS-group. 
Highest utilization in the RP-group is found for the RP surgery without complications and 
monitoring after surgery by an urologist. Both treatments are utilized by 99% of individuals 
in the RP-group. It is assumed in the model that 100% of individuals in the RP-group receive 
these treatments; the utilization simulated during 10 cycles is less, because 2 individuals die 
before treatment (Table A-3 appendix). Health technologies for the treatment of ED and IC 
also have a high utilization in the RP-group (73% and 43%).  
Individuals under AS predominantly utilize technologies that relate to the surveillance itself 
(99%). Again, AS is assumed to be utilized by all individuals in this group, but utilization is 
lower because of early mortality. About 15% of individuals under AS receive a RP surgery and 
are monitored after the surgery.  
Treatment of ED and IC is considerably lower in the AS-group than in the RP-group with 12% 
vs. 73% and 7% vs. 43%, respectively. Pharmaceutical treatment of BPH is utilized by 33% of 
individuals in the AS-group, as compared to no utilization in the RP-group; by assumption 
BPH is cured in the RP-group by the initial surgery. In the remaining cost groups utilization is 
low (<5%) in the AS- and the RP-group. Due to the early death of 4 individuals (2 in each 
treatment group), total utilization of any health technology amounts to 99%. 
In both treatment groups per capita costs, accumulated during follow-up, are highest for RP 
surgery (RP: mean €6,843, STD 543, median 6,886, interquartile range 0; AS: mean €1,051, 
STD 2,480, median 0, interquartile range 0) (Table A-3 appendix). In the RP-group €1,073 per 
person (STD 85, median 1,080, interquartile range 0) arise for monitoring after the surgery; 
€889 per person (STD 884, median 189, interquartile range 1,890) accrue due to the 
treatment of ED. For the surveillance of individuals under AS on average €416 (STD 111, 
median 463, interquartile range 0) are spent over the study duration of 2.5 years. 
For cost groups with low utilization estimates of per capita costs are extremely uncertain, 
indicated by large absolute values of STD. This is, for example, the case for IC surgery; in 
both treatment groups mean costs are low (€31 and €63) while STDs are high (€562 and 
€794). Total per capita costs amount to €9,712 (STD 2,585, median 9,856, interquartile range 
1,505) in the RP-group and €2,220 (STD 3,354, median 463, interquartile range 1,080) in the 
AS-group, respectively. 
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Cost group Incremental costs (€) AS vs. RP 
 m STD
ED -818 652 
IC -214 379
RP w/o complications -5,792 1,795 
AS 416 79
EBRT 0 0 
Urosepsis 96 378 
TURP 0 0 
Surgery IC 31 688
Surgery ED -448 1,341
RP with complications -298 1,390  
BPH  317 336
Stricture  -88 291 
Monitoring RP -908 282
Total -7,492 2,994 
m=mean 
Table 4-13: Disease-related, per capita incremental costs (€), 
by cost group – microsimulation (PCa-model) 
The comparison of per capita costs shows that in the AS-group €5,792 (STD 1,795) less is 
spent on RP surgery without complications (Table 4-13). Treatment of ED (€-818, STD 652) as 
well as monitoring after RP surgery (€-908, STD 282) are also less costly in the AS-group. 
Costs of surveillance, on the other hand, are by €416 (STD 79) higher in the AS-group than in 
the RP-group. 
Generally, individuals in the AS-group incur fewer costs than individuals in the RP-group in 7 
out of 13 cost groups. Total per capita costs are by €7,492 (STD 2,994) lower in the AS-group 
than in the RP-group in the microsimulation of the decision model. 
4.5.2.2 Monte Carlo simulation 
By using Monte Carlo simulation, 95% CIs of per capita costs are estimated per cost group 
and treatment strategy; for incremental costs p-values are estimated. 
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Similar to results of microsimulation, highest per capita costs in both treatment strategies 
are incurred by RP surgery with (RP: €6,950, CI [5,392; 8,677]; AS: €1,028, CI [638; 1,534]) or 
without complications (RP: €6,826, CI [5,291; 8,551]; AS: €1,010, CI [627; 1,515]) (Table 
4-14). The range of CIs shows, though, that considerable uncertainty is present in the cost 
estimates. 
Not considering cost groups with null costs, lowest per capita costs incurs IC surgery in the 
RP-group (€19, CI [8; 36]); treatment of BPH by TURP (€4, CI [4; 4]) and surgery due to ED 
(€4, CI [2; 7]) incur lowest costs in the AS-group. Total per capita costs, as estimated by 
Monte Carlo simulation, amount to €9,627 (CI [8,009; 11,387]) in the RP-group and to €2,141 
(CI [1,662; 2,738]) in the AS-group, respectively. 
Cost group 
Costs p.p. (€) 
RP AS 
m    95% CI m    95% CI 
ED 837        608 to 1,095 69      42 to 106 
IC 240            0 to 1,960 26    15 to 39 
RP w/o complications 6,826     5,291 to 8,551 1,010       627 to 1,515 
AS 0     0 to 0 417    404 to 428 
EBRT 0     0 to 0 0    0 to 0 
Urosepsis 0    0 to 0 95      37 to 183 
TURP 0    0 to 0 4    4 to 4 
Surgery IC 19      8 to 36 33    18 to 53 
Surgery ED 415    286 to 589 4    2 to 7 
RP with complications 6,950    5,392 to 8,677 1,028       638 to 1,534 
BPH  0    0 to 0 297    227 to 376 
Stricture  69    61 to 77 10       7 to 14 
Monitoring RP 1,075    1,075 to 1,075 159     104 to 220 
Total 9,627     8,009 to 11,387 2,141     1,662 to 2,738 
m=mean  
Table 4-14: Disease-related, per capita costs (€), by cost group – Monte Carlo simulation 
(PCa-model) 
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When comparing per capita costs estimated in Monte Carlo simulation, the highest cost 
difference between AS and RP is found for RP surgery with (€-5,922, CI [-7,480; -4,589], 
p<0.0001) and without complications (€-5,816, CI [-7,339; -4,493], p<0.0001) (Table 4-15); 
these differences are highly significant. The AS scheme incurs significantly higher costs in the 
AS-group than in the RP-group (€417, CI [404; 428], p<0.0001), which corresponds to the 
model assumption that AS is not performed after RP surgery. Pharmaceutical treatment of 
BPH is also significantly more costly in the AS-group than in the RP-group (€297, CI [227; 
376], p<0.0001). 
Overall, 7 out of 13 cost groups incur higher costs in the RP-group than in the AS-group and 
cost differences in all of these are highly significant (p<0.0001). Total costs of the AS-group 
are significantly lower by €7,486 (CI [-9,059; -6,093], p<0.0001) than total costs of the RP-
group. 
Cost group 
Incremental costs (€) AS vs. RP 
m       95% CI p-value
ED -769     -1,003 to -552 < 0.0001
IC -236        -317 to -167 < 0.0001
RP w/o complications -5,816        -7,339 to -4,493 < 0.0001
AS 417        404 to 428 < 0.0001
EBRT 0        0 to 0 -
Urosepsis 95          37 to 183 < 0.0001
TURP 4        4 to 4 < 0.0001
Surgery IC 13        -7 to 33 < 0.0001
Surgery ED -411       -584 to -282 < 0.0001
RP with complications -5,922       -7,480 to -4,589 < 0.0001
BPH  297       227 to 376 < 0.0001
Stricture  -59       -66 to -51 < 0.0001
Monitoring RP -916       -971 to -856 < 0.0001
Total -7,486       -9,059 to -6,093 < 0.0001
m=mean 
Table 4-15: Disease-related, per capita incremental costs (€), by cost group –
Monte Carlo simulation (PCa-model) 
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4.6 Comparison between model and claims data 
Results of the comparison between outcomes of the PCa-model and AOK claims data are 
presented in the following; methods for outcome comparison are described in step 6 of the 
validation approach. 
4.6.1 Input parameters: resource use and unit costs 
The PCa-model, generally, assumes that the quantity of resource utilization is identical in the 
AS- and the RP-group (Table 4-12). Claims data analysis, however, shows that resource use 
differs between the treatment groups; individuals in the AS-group have higher resource use 
than individuals in the RP-group in outpatient treatment, pharmaceuticals, assistive 
technologies, and physiotherapy (Table 4-8). The exception is outpatient follow-up of RP 
surgery (RP: 8.62, AS: 3.50) and physiotherapy as a treatment of incontinence (RP: 22.52, AS: 
17.00), where resource use is lower in the AS-group. 
Inpatient procedures are utilized once, both in AOK dataset and model, with the exception 
of TURP in the AS-group (AOK) which is utilized 2 times by one of the treated individuals. The 
quantity of utilized outpatient procedures is higher in the PCa-model in case of follow-up of 
RP surgery (AOK: 8.62 and 3.50, model: 10.00) and surveillance of AS individuals (model: 
9.00, AOK: 7.36). The model assumes lower resource use for all remaining outpatient 
procedures than estimated in claims data analysis for both treatment groups. 
The number of pharmaceutical prescriptions varies widely between AOK estimates and 
model input parameters; claims data analysis estimates lower resource use throughout. 
Especially consumption of PDE5 inhibitors for the treatment of ED is, with 1 prescription, 
considerably lower than assumed in the model (22 prescriptions). In this case, the AOK 
estimate is probably too low, because PDE5 inhibitors are generally not covered by SHI; thus, 
prescriptions are not coded in AOK data. This is also the explanation for lower estimated 
utilization of assistive technologies for the treatment of ED in claims data (RP: 1.00, AS: 1.00) 
than in the model (10.00).  
The PCa-model assumes equal unit costs of health technologies for the AS- and the RP-
group. Unit costs estimated in claims data analysis are overall comparable between 
treatment groups, which supports the assumption of equal unit costs in the model. 
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Unit costs of inpatient procedures are comparable between the AOK data analysis and the 
PCa-model. Unit costs of inpatient treatment of stricture (AOK: €4,298; model: €2,010) and 
artificial urethral sphincter surgery (AOK: €11,732; model: €6,394), however, are about 2 
times higher in claims data analysis than assumed in the decision model. Both claims data 
estimates are based on an extremely low number of observations, which limits validity 
considerably. Unit costs included in the model may be more valid in this case. 
In outpatient treatment, unit costs of EBRT are considerably overestimated in the PCa-model 
with €4,742, in comparison to €1,380 estimated in claims data analysis. Here, claims data 
analysis is based on a number of observations sufficient to estimate valid unit costs of EBRT.  
In case of pharmaceutical treatment, unit cost estimates vary widely between claims data 
analysis and decision model. Especially, unit costs of pharmaceutical treatment of BPH (AOK: 
€47; model: €108) and ED (AOK: €23; model: €114) included in the model are 2 and 5 times 
higher, respectively, than claims data estimates. As described previously, pharmaceutical 
treatment of ED is usually not covered by SHI and unit cost estimates may, thus, be limited in 
their validity.     
4.6.2 Simulation outcome: probability of utilization and per capita costs 
4.6.2.1 Unadjusted claims data analysis vs. microsimulation model 
Figure 4-4 and Figure 4-5 show the comparison of utilization probability, as estimated in 
claims data analysis and microsimulation of the model, for the AS-group and the RP-group, 
respectively. Estimates of utilization probability of the initial treatment (AS or RP with/ 
without complications) and of total costs are equal in both data sources (AOK: 100%, model: 
99%) (see also Table A-2 and Table A-3 appendix). However, claims data analysis estimates a 
considerably higher probability of RP with complications (19%) compared to the model (4%).  
In microsimulation of the PCa-model treatment of ED is utilized by 12% in the AS-group 
compared to just 7% estimated in claims data analysis, respectively. In the RP-group the 
estimate of ED-treatment is also considerably lower in claims data analysis than in 
microsimulation (AOK: 15%, model: 73%). As described previously, claims data analysis is 
limited in this respect, because treatment of ED is covered by SHI in exceptional cases only. 
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Figure 4-4: Probability of utilization (%) in AS-group, by data source 
 
 
Figure 4-5: Probability of utilization (%) in RP-group, by data source 
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Treatment of IC is similar in AOK dataset and model, with 7% and 9% in the AS-group and 
44% and 43% in the RP-group. The PCa-model assumes that in 15% of individuals in the AS-
group a RP surgery is performed in follow-up, whereas this number is estimated to be 
considerably lower in claims data (4%). 
As assumed in the PCa-model, EBRT is not performed at all during follow-up after AS, 
whereas claims data analysis shows that EBRT is utilized by 10% of individuals in the AS-
group. Equal results are found for the treatment of BPH by TURP, where the model assumes 
no utilization, whereas in claims data analysis 9% of AS-individuals are treated. 
Treatment of urosepsis, surgery for IC and ED, and treatment of stricture have an equally 
low probability of utilization in both datasets and treatment strategies. 
 
Figure 4-6: Total disease-related, per capita costs (€), by treatment strategy and data source 
When comparing unadjusted incremental costs estimated in claims data analysis and 
incremental costs simulated in the model, the largest deviation is found for RP surgery with 
complications. Mean incremental costs in AOK dataset (€-1,943, STD 3,624) are about 6.5 
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times higher than simulated incremental costs in the model (€-298, STD 1,390). Both, 
however, suggest that costs in the AS-group are lower than in the RP-group. 
Generally, in cost groups where the PCa-model simulates lower costs for the AS-group, this 
relationship is also found in claims data analysis. The exception is inpatient treatment of 
urosepsis, where claims data analysis estimates that the AS-group has slightly lower mean 
costs than the RP-group (€-10, STD 306), whereas the model simulates by 96€ (STD 378) 
higher costs per individual in the AS-group. 
Total incremental costs estimated in unadjusted claims data analysis (€-6,054, STD 3,733) are 
€1,438 (19%) lower than total incremental costs simulated in the PCa-model (€-7,492, STD 
2,994). Figure 4-6 pictures the distribution of total incremental costs estimated in claims 
data analysis and microsimulation of the model for the AS- and the RP-group separately (for 
comparison of single cost groups see figure A-1 in appendix). 
4.6.2.2 Adjusted, bootstrapped claims data analysis vs. Monte Carlo simulation model 
 
Figure 4-7: Histogram of total incremental costs estimated by excess cost analysis and Monte 
Carlo simulation (€), by data source 
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Excess costs of the AS-group estimated in adjusted, bootstrapped claims data analysis 
amount to €-6,611 (CI [-9,734; -3,547]), as described previously. Monte Carlo simulation of 
the PCa-model reports total incremental costs of €-7,486 (CI [-9,059; -6,093]). The difference 
between the claims data and model estimate amounts to €875 (CI [-2376; 4301]). A p-value 
of 0.605, estimated via bootstrap hypothesis testing, suggests a significant agreement 
between estimates on the 95% level, which is not due to random variation in both datasets. 
Figure 4-7 shows a graphical overlap of the distributions of mean excess costs generated by 
bootstrapping of claims data and Monte Carlo simulation, respectively. 
For the comparison of incremental costs estimated in disease-related cost analysis with 
model outcomes, the difference in costs between AOK data and model is calculated for each 
cost group individually in addition to total costs (Table 4-16).  
Cost group 
Mean 
AOK
Mean 
model
Difference 
AOK-model
95% CI p-value
ED -19 -769 750       530 to 986 0.004
IC -133 -236 103        10 to 199 0.038
RP w/o complications -4,806 -5,816 1,011       -400 to 2,527 0.186
AS 88 417 -383       -342 to -313 <0.0001
EBRT 271 0 271       119 to 469 <0.0001
Urosepsis -13 95 -108        -212 to -8 0.040
TURP 771 4 768         183 to 1,788 <0.0001
Surgery IC 60 13 46       -28 to 314 0.936
Surgery ED -34 -411 377      216 to 556 <0.0001
RP with complications -1,986 -5,922 3,936     2,406 to 5,602 <0.0001
BPH  140 297 -157       -244 to -69 <0.0001
Stricture  -181 -59 -122       -364 to 62 0.214
Monitoring RP -131 -916 785       723 to 840 <0.0001
Total -6,260 -7,486 1,226   -621 to 2,937 0.180
Table 4-16: Comparison of disease-related incremental costs in claims data and model, 
by cost group 
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Significant overlap – corresponding to a p-value larger than 0.05 – between claims data 
estimate and model estimate is found for RP with complications (€1,011, CI [-400; 2,527], 
p=0.186), surgery for IC (€46, CI [-28; 314], p=0.936), inpatient treatment of stricture (€-122, 
CI [-364; 62], p=0.214), and total costs (€1,226, CI [-621; 2,937], p=0.180). Figure 4-8 shows 
results of total incremental cost comparison graphically and strengthens the notion that 
confidence limits of both estimates significantly overlap (for comparison of single cost 
groups see Figure A-2 in appendix). 
P-values of treatment of IC (p=0.038) and urosepsis (p=0.040) are just below the threshold 
for significant agreement, in all remaining cost groups highly significant difference in 
estimates is indicated (p<0.0001). 
 
Figure 4-8: Histogram of disease-related total incremental costs estimated by adjusted 
claims data analysis and Monte Carlo simulation (€), by data source 
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4.7 Sensitivity analyses 
Results of sensitivity analysis described in step 7 of the validation approach are presented in 
the following. 
4.7.1 Incident PCa-cases in claims data analysis 
In the first sensitivity analysis, including only incident PCa-cases, excess costs and total 
disease-related costs are analyzed for an age-matched cohort of 192 men (AS: 64, RP: 128). 
Mean age in the incident cohort is 72 years, 2 years older than the base case cohort. 
Excess cost analysis reveals that mean co-morbidity adjusted costs of AS increase by €1,650 
to €13,358 (CI [9,698; 17,308]) in total compared to base case. Per capita costs of the RP-
group (€18,641, CI [16,216; 22,107]), on the other hand, do not change notably compared to 
the base case. AS is still significantly less costly than RP (€-5,283, CI [-9,585; -1,101], 
p=0.016), though. When comparing excess costs of claims data analysis with model 
simulation outcome (€-7486), a difference in incremental costs of €2,202 (CI [-2,132; 6,652]) 
is found. A p-value of 0.342 indicates that a significant agreement between estimates of 
excess cost analysis and model simulation is indicated. 
The analysis of disease-related costs of the incident PCa-cohort reports only results of total 
costs, because estimation of valid costs of single health technologies is not possible due to 
very small numbers of treated patients. Bootstrapped and co-morbidity adjusted analysis 
estimates total costs of €7,793 (CI [7,185; 8,619]) in the RP-group and €1,976 (CI [885; 
3,328]) in the AS-group, respectively. As in excess cost analysis, total costs of the RP-group 
are almost unchanged, whereas costs of the AS-group increase by €375 compared to base 
case analysis. Despite this increase, AS is still significantly less costly than RP (€-5,817, CI [-
7,300; -4,213], p<0.0001) in the incident PCa-cohort. When comparing outcomes of disease-
related cost analysis with total incremental costs simulated in the PCa-model (€-7,486) a 
mean difference of €1,670 (CI [-388; 3720], p=0.106) is found. In addition to this result, 
Figure 4-9 indicates that there is a significant overlap between estimates of incident claims 
data analysis and model simulation. 
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Figure 4-9: Histogram of disease-related total incremental costs (€) in incident PCa-cohort, 
by data source 
4.7.2 Age distribution in the decision model 
To test the influence of age at treatment initiation on total costs, the PCa-model is run twice; 
first with a mean age of 51 years at treatment initiation and corresponding age-dependent 
transition probabilities, secondly with a mean age of 79 years, respectively.  
In the model with mean age of 51 years at treatment initiation, the probability of utilization 
of any health technology is 100%. No deaths occur in the follow-up period, owing to the 
considerably lower mortality rates in this age group. Monte Carlo simulation reports per 
capita costs of €9,682 (CI [8,058; 11,450]) in the RP-group and €2,178 (CI [1,691; 2,786]) in 
the AS-group respectively, which are not notably different from base analysis. Incremental 
cost analysis shows that per capita costs in the AS-group are by €-7,505 (CI [-9,079; -6,106], 
p<0.0001) significantly lower than in the RP-group. Comparison of model incremental costs 
with incremental costs from disease-related claims data analysis reports a difference of 
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€1,245 (CI [-612; 2,966], p=0.172), which indicates a significant agreement between 
estimates (Figure 4-10). 
 
Figure 4-10: Histogram of disease-related total incremental costs (€) in PCa-model cohort 
with mean age of 51 years, by data source 
When the PCa-model assumes an age of 79 years at treatment initiation, utilization of health 
technologies is reported for 97.8% of individuals in the cohort. Due to an increase in 
mortality in this age group, 7 individuals in each treatment group die early in the follow-up 
period and incur no costs. In Monte Carlo simulation per capita costs of €9,445 (CI [7,846; 
11,181]) are estimated for individuals in the RP-group and €1,542 (CI [1,267; 1,852]) for 
individuals in the AS-group, respectively. These estimates of per capita costs are slightly 
lower than estimates of base case analysis, which is due to the higher number of 
observations with 0 costs. Furthermore, all individuals in the AS-group progressing to radical 
treatment are treated by EBRT and not RP, because of age-based assumptions in the model. 
This has the effect that total costs of the AS-strategy decrease compared to the base case, 
because EBRT is less costly than RP surgery.  This is also reflected in incremental cost 
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analysis; total costs in the AS-group are significantly lower by €7,903 (CI [-9,628; -6,336], 
p<0.0001) than in the RP-group. In the base case analysis, in contrast, incremental costs 
amount to €-7,486 (CI [-9,059; -6,093]). In comparison to incremental costs of disease-
related claims data analysis a difference of €1,644 (CI [-211; 3,530]) is found. A p-value of 
0.08 indicates a significant agreement between estimates (Figure 4-11). 
 
Figure 4-11: Histogram of disease-related total incremental costs (€) in PCa-model cohort 
with mean age of 79 years, by data source 
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5 Discussion 
5.1 Interpretation of results 
5.1.1 Patient cohort 
The mean age in the claims data cohort is 70 years at treatment initiation which is replicated 
in the model cohort. Based on evidence from RCTs the PCa-model assumes that no co-
morbidity is present in the cohort at treatment initiation; claims data analysis, however, 
shows that this is not reflected in treatment practice. Especially BPH is a common co-
morbidity in the AS- and the RP-group with rates of 68% and 77%, respectively. ED is also 
present at baseline in both treatment groups with rates of 5% and 11%, respectively. The 
difference in baseline co-morbidity between treatment groups in claims data analysis is 
probably conditioned by the initial treatment decision; men with BPH and ED tend to radical 
therapy because their symptoms are cured as well. To account for this difference, costs are 
adjusted for co-morbidity in claims data analysis. 
During cohort selection in the claims dataset, the majority of PCa-cases are lost in the 
process of assignment to treatment groups; 25,293 individuals are identified as valid PCa-
cases, whereas only about 1,000 individuals are included each in the AS- and the RP-group, 
another 1,000 individuals are treated by EBRT (before limitation to localized PCa disease). 
This might be explained by comparatively higher prevalence rates than incidence rates in 
Germany; most PCa-cases in the AOK data set are not newly diagnosed and are, thus, not 
treated by AS, RP, or EBRT. The analysis of incident PCa-cases with no PCa-diagnosis before 
initial treatment supports this assumption; the number of individuals with a validated PCa-
diagnosis decreases to 5,720. Individuals excluded from the claims data cohort are either in 
an advanced stage of PCa disease and are, thus, treated with other therapies than analyzed 
here. Alternatively, individuals are under WW because of advanced age. It is also possible 
that individuals with localized PCa were treated before beginning of the study period and 
PCa-diagnosis is still coded in the claims dataset, due to the coding practice in Germany. 
Mortality rates in the claims data cohort and the model cohort differ significantly. Compared 
with the annual mortality rate of the male German population for the age group of 70 years 
(2.3%), mortality in the decision model (0.62%) is notably lower; mortality in the claims data 
cohort is notably higher in the AS-group (7.5%), whereas mortality rates in the RP-group 
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(2.8%) accord with rates of the German population. One reason for the notable difference in 
mortality rates between treatment groups in claims data analysis might be that follow-up of 
AS-patients begins on average 12 months later than follow-up of RP-patients; AS-patients 
are, thus, on average 12 months older than RP-patients. Mortality rates do, however, not 
increase so notably in the general German population in the course of 12 months.  
As overall and PCa-specific mortality cannot be differentiated in claims data no inference on 
effectiveness of treatment strategies based on mortality rates is possible. The extreme 
difference in mortality rates between the treatment strategies in the claims data analysis 
and between claims data and decision model influences, however, analysis of resource use 
and costs. The comparatively higher mortality rate in the AS-group may, on the one hand, 
lead to an underestimation of health technology utilization, because due to the premature 
death fewer resources are utilized by these individuals than by individuals surviving in the 
study duration. On the other hand, evidence suggests that health care utilization and costs 
are significantly higher in end-of-life care, 6 months before death, than in the phases of 
initial treatment and follow-up, which might lead to an overestimation of costs of the AS-
strategy compared to the RP-strategy (137). 
5.1.2 Claims data and model analysis 
Claims data analysis shows that individuals with RP surgery experience significantly more 
complications in follow-up (49%) compared to individuals under AS (12%). These 
complication rates should, however, be interpreted in the light of the limitations of analysis 
of effectiveness in the AOK dataset described in chapter 5.3.  
The PCa-model does not report complication rates; however, it is shown that the RP-strategy 
generates less QALYs than the AS-strategy, which predominantly originates in the quality of 
life loss due to complications of ED and IC after RP-surgery. 
Excess cost analysis and disease-related cost analysis of AOK claims data both show that 
overall AS is the less costly strategy compared to RP, with total incremental costs of €-6,611 
and €-6,260, respectively.   
Considering excess costs only, AS is significantly less costly than RP in inpatient care which 
originates mainly in the high costs of the hospital stay of the initial RP surgery (€-5,845). 
Disease-related cost analysis confirms this; the AS-group incurs €4,805 less for RP surgery 
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without complications and €1,986 less for RP surgery with complications. The difference in 
costs of RP surgery predominantly accounts for the total difference in costs between 
treatment groups, in excess cost analysis as well as in disease-related cost analysis. PCa-
model simulation reports this as well; the difference in costs of RP surgery (€-5,816) 
constitutes the predominant part of total incremental costs of €-7,486.    
Excess cost analysis reports that, compared to RP, outpatient care is less costly under AS (€-
961) in the period of 2.5 years follow-up, even though the main costs of AS arise in 
outpatient care. In disease-related analysis, outpatient treatment is further categorized in 
treatment with single health technologies and results show a more differentiated picture of 
outpatient care; in the AS-group costs of the surveillance scheme itself (€88) and EBRT 
(€271) incur higher costs than in the RP-group. Outpatient treatment of ED (€-19) and IC (€-
133) as well as monitoring after RP surgery by an urologist (€-131) is less costly in the AS-
group. In the decision model cost differences are larger, but point to the same conclusion 
that outpatient surveillance is more costly in the AS-group (€417), while outpatient 
treatment of ED (€-769), IC (€-236), and monitoring after RP surgery (€-916) are significantly 
less costly than in the RP-strategy. The AS- and the RP-strategy, generally, show different 
cost patterns; the RP-strategy incurs high initial outpatient costs (e.g. for monitoring after 
the surgery) while costs of AS are more equally distributed over time (102, 104, 105, 138).  
Pharmaceutical treatment of BPH is more costly in the AS-group, as estimated by disease-
related claims data analysis (€140) and Markov model analysis (€297). Excess cost analysis 
does not explicitly analyze BPH treatment; however, overall costs of pharmaceutical therapy 
are by €587 higher in the AS-group than in the RP-group.  
Furthermore, excess cost analysis of claims data shows that costs of assistive technologies - 
mainly incontinence aids - are significantly higher in the RP-group by €141, attributable to 
the higher IC rate in the RP-group. When complication is included as a variable in the 
regression analysis of claims data, a significant increase in costs for assistive technologies is 
found for individuals with complications. In disease-related claims data analysis and Markov 
model simulation utilization of assistive technologies is included in the cost groups ED and IC 
which both incur higher costs in the RP-group than in the AS-group, as described previously.  
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5.1.3 Comparison between model and claims data 
No significant differences between the claims data estimate and model estimate of 
incremental costs are found for RP surgery without complications, surgery in case of IC, and 
surgical treatment of a stricture. The incremental cost estimate of RP surgery is based on a 
large number of observations and is afflicted by relatively little variability in the parameter 
estimates of the two treatment groups; the estimate of claims data analysis is very likely 
representative for costs incurred by AOK. The agreement between AOK and model estimate 
can be interpreted as sufficient to assume that the PCa-model simulates costs of RP surgery 
validly. Cost estimates of IC surgery and treatment of stricture, on the other hand, are based 
on a small number of observations in claims data analysis; the same limitation is found in 
PCa-model analysis. Both estimates of incremental costs are afflicted by considerable 
uncertainty, which is represented in wide 95% CIs. Even though an agreement between both 
estimates is found, it remains unclear whether the model predicts costs of IC and stricture 
surgery in treatment practice validly. However, in the interest of the decision maker 
validating the PCa-model total cost difference is most important. As described previously, 
the cost difference in RP surgery is the best indicator of the total cost difference and this 
parameter is predicted validly by the decision model. 
No agreement between claims data and model estimate could be found in the remaining 
cost groups; this finding stems from different sources. In case of costs of the AS scheme for 
example, the model assumes higher resource use and unit costs than observed in claims 
data analysis, which in turn leads to about 4.5 times higher incremental costs of the AS-
strategy in the decision model than in claims data. In case of EBRT treatment, on the other 
hand, no patients in both treatment groups receive this treatment in the decision model, 
whereas individuals in the AS-group in claims data analysis are treated by EBRT; 
consequently, no agreement of incremental cost estimates of claims data and model is 
found for EBRT treatment. 
Overall, an agreement between total incremental cost estimates of excess cost analysis as 
well as disease-related cost analysis of claims data and PCa-model exists. P-values of 0.61 
and 0.18, respectively, show a significant agreement of total incremental costs estimated by 
claims data analysis and PCa-model simulation. Results are robust to both changes to the 
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claims data cohort (incident PCa-cases; p=0.342) and changes to the model cohort (age 51 
years: p=0.172, age 79 years: p=0.08). 
The question arises whether inferring lifetime costs of AS compared to RP based on the 
validation of short-term resource use and costs of the PCa-model is possible: Incremental 
total costs of AS compared to RP in the short-term decision model amount to €-7,486, which 
show significant agreement with the observed incremental costs of €-6,260 in claims 
analysis; incremental costs are almost exclusively due to the high costs of the initial RP-
surgery, both in model and claims data analysis. In the published PCa-model by Koerber et 
al., which evaluates a patient cohort of men aged 65 years in a lifetime perspective, 
incremental costs of AS compared to RP amount to €-6,883, which are also due to the costs 
of the initial RP-surgery. As the simulation of short-term costs is valid, it is very likely that 
long-term costs simulated by the decision model are valid as well. Inferring the validity of 
effectiveness outcome and, following this, cost-effectiveness outcome of the PCa-model is 
not possible based on this validation, though, because quality of life outcome cannot be 
assessed validly in AOK claims data.  
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5.2 Comparison with literature 
5.2.1 Literature on PCa treatment 
Rates of short- and long-term ED after RP (15% and 12%) estimated in claims data analysis 
are considerably lower than rates reported in clinical trials. A recent meta-analysis by Ficarra 
et al. (2012) reports ED rates of about 35%-75%, 12 months after surgery (75). In the PCa-
model short-term ED occurs in 39% of individuals in the RP-group and long-term ED in 35%, 
respectively, based on data from a meta-analysis by Ollendorf et al. (2009) (114).  
According to claims data analysis, 6% of individuals in the AS-group develop ED in the follow-
up period. In comparison, a study by Braun et al. (2014) reports an ED rate of roughly 35% in 
a cohort of men under AS at baseline; even without possible decrease of erectile function 
due to repeat prostate biopsies, ED rates are considerably higher than in the AOK cohort. ED 
rates are generally underestimated in the AOK dataset, because treatment of ED is usually 
not covered by SHI and, thus, diagnoses are not validly coded. 
Claims data analysis reports rates of IC after RP of 44% (short-term) and 33% (long-term). 
These rates are slightly higher than the IC rate reported in a meta-analysis by Ficarra et al. 
(2012) of about 20%, 12 months after surgery (74). IC rates included in the model (short-
term 9%, long-term 2.5%) are, however, considerably lower than rates of claims data 
analysis (114). In case of IC, treatment is covered by SHI and diagnoses are validly coded in 
AOK dataset. It is, however, not possible to distinguish age-related and surgery induced 
decline of urinary function in SHI data. This may be a reason for the higher IC rates reported 
in AOK data analysis compared to published evidence.  
Validity of ED and IC rates also influences validity of cost estimates of ED and IC treatment. In 
case of ED treatment in the AS-group, for example, estimates of unit costs may not be valid 
due to a small number of observations.  
Anderson et al. (2011) compare costs of RP and WW in a study based on data from the 
SPCG-4 trial (96); the authors calculate unit costs of penis prosthesis surgery of €7,010, 
similar to the unit cost estimate of claims data analysis (€7,586) presented in this study. 
Anderson et al. (2011) estimate per capita costs of penis prosthesis surgery in the RP-group 
of €131 over a study duration of 12 years. AOK claims analysis, however, estimates lower 
costs of about €36 per individual in the RP-group, which is on the one hand due to the 
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considerably shorter follow-up period; on the other hand, per capita costs are 
underestimated in SHI claims because ED-cases are not comprehensively included in the 
analysis. 
Unit costs of IC surgery (€9,072) based on the SPCG-4 trial are similar to unit cost estimated 
in claims data analysis (€8,799). Even though the number of individuals with IC surgery is 
very low in the AOK data set, the estimate of unit costs is comparable to published costs. 
However, per capita costs in AOK data analysis for IC surgery (RP: €55, AS: €110) are 
considerably lower than in the SPCG-4 trial (RP: €1,017, WW: €86), due to the shorter follow-
up period. 
Anderson et al. (2011) estimate unit costs of €6,031 for RP surgery, similar to the unit costs 
presented in this study (€6,356). Per capita costs of RP surgery accumulate to €7,732 in the 
RP-group and €746 in the AS-group, as estimated by the SPCG-4 trial; in AOK claims analysis 
unit costs amount to €5,051 and €246, respectively. AOK estimates are lower than SPCG-4 
trial estimates; however, in both studies per capita costs of RP surgery are significantly 
higher in the RP-group than in the AS-group with a p-value lower than 0.0001. In the SPCG-4 
trial, costs attributable to the WW scheme (physician contacts and laboratory tests) do not 
differ between treatment strategies, because WW does not have such a strict surveillance 
scheme as AS. 
Over a study duration of 12 years, total incremental costs of €6,123 between the WW- and 
the RP-strategy are estimated based on SPCG-4 data, corresponding to results of claims data 
and model analysis presented here. Despite differing length of study duration in claims data 
analysis and PCa-model simulation compared to the study by Anderson et al. (2011), the cost 
difference is driven almost exclusively by the costs of RP surgery in all 3 studies. 
As described in chapter 2.2, several US-based modeling and observational studies with 
comparable patient cohorts and time horizons show that the AS-strategy or the CM-strategy 
(including AS and WW) are least costly over the whole study duration (78, 97, 99, 102, 103). 
Only the study by Perlroth et al. (2012) reports that from year 2 of the study on costs of CM 
become equal to RP (100). Perlroth et al. do not state unit costs of the surveillance scheme; 
however, other US-based studies show that the unit costs of prostate biopsy ($605-$1,102) 
alone are considerably higher in the US health-care context than unit costs of the whole 
surveillance scheme (PSA testing and biopsy) in Germany (€44) (78, 102, 103).  
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Results presented here suggest that in an European health care context - contrary to US 
health care - cost differences between AS and RP arise in the first years after treatment and 
do not converge in a lifetime perspective because of the relatively low costs of the AS 
scheme (101).  
5.2.2 Literature on model validation 
In a qualitative literature search several studies are found which validate decision models 
with external data sources (20-25). Both studies by Palmer et al. (2004) and McEwan et al. 
(2014) use published RCT data to externally validate complication and mortality rates of the 
CORE diabetes model (22, 24). Similarly, Eddy and Schlessinger (2003) conduct an external 
validation of the Archimedes diabetes model with RCT data, which are not incorporated in 
the decision model (23). The study by Ishida et al. (2008) employs data from medical records 
to externally validate survival rates predicted by a Markov model which compares treatment 
for hepatitis C virus-related hepatocellular carcinoma (20). Van Staa et al. (2013) validate 
several RCT-based decision models comparing costs and effects of nonsteroidal anti-
inflammatory drugs and selective cox-2 inhibitors with outcomes from a claims data based 
simulation model (21). Stollenwerk et al. (2009) validate a Markov model for coronary artery 
disease risk screening in Germany with empirical data from an observational study (25). 
In addition, 2 studies are found which do not validate a decision model, but give indications 
on the methodological approach to validation with external data sources. For one, Bratzler 
et al. (2011) validate a claims data based regression model which predicts 30-day hospital 
mortality by mortality rates reported in medical records (32). Secondly, a study by Janson et 
al. (2005) conducts an economic evaluation of open versus laparoscopic surgery for colon 
cancer based on self-reported patient data from a clinical trial; self-reported data of a subset 
of study participants are validated with data from medical records and social security claims 
(31). 
This study compares outcomes independently observed in the trial and predicted in the 
decision model; evidence from the external trial is not incorporated in the decision model as 
in the studies by Ishida et al. (2008) and Stollenwerk et al. (2009) (20, 25). 
In contrast to studies changing characteristics of the decision model (21-24), the aim of the 
study presented here is to validate the decision model as it was originally designed and avoid 
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changes to the model as far as possible; instead, the cohort of the external data source – the 
AOK dataset – is adapted to the model’s cohort. Likewise, the study design assumed in the 
model, including length of follow-up and treatment strategies, is replicated in the external 
data source in this study. However, adaptation of the external data source is limited to 
available parameters; demographic information, for example, is not sufficient in the AOK 
dataset to replicate all cohort characteristics of the PCa-model, as it is possible in the study 
by Ishida et al. (2008) which uses detailed information from medical records (20). 
This replication of model characteristics in the external dataset is possible, because AOK data 
are originally analyzed for the purpose of model validation, contrary to studies where 
external evidence stems from published studies (22-25). 
In this study, as proposed in the literature, the output of the external data source and the 
decision model are plotted graphically in form of histograms such that the horizontal axis 
denotes costs and the vertical axis denotes the observed and simulated values, respectively 
(29, 30). 
As statistical tests are recommended in addition to graphical analysis to obtain quantitative 
information about the validity of the decision model, in this study a hypothesis test based on 
bootstrapping is employed. It is tested whether the point estimate of the external data 
source is included in the model’s CI and the other way round (22, 25, 30). By using bootstrap 
hypothesis testing the problems of other test statistics, such as the Student t-test, described 
in chapter 1.2.3, are avoided. 
Furthermore, linear regression analysis is proposed in the literature to compare observed 
and simulated outcomes (22, 24, 32). A prerequisite for regression analysis is that pairs of 
patients (paired observations) are present in model simulation and observed data. 
Observations are not paired in this study, though, and consequently linear regression 
analysis would estimate correlation for random pairs of observations. No conclusion on the 
validity of the decision model can be drawn from linear regression analysis in this study. 
Studies comparing outcomes of different decision models apply goodness of fit tests to 
assess validity of the validated model (22, 33). In this study, outcomes of the decision model 
are compared with independently analyzed outcomes in claims data, so tests for goodness 
of model fit are not relevant to assess the validity of the PCa-model.  
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5.3 Strengths and limitations 
In the following, the proposed approach for the validation of decision models based on 
claims data is discussed by highlighting strengths and limitations of claims data in the 
individual validation steps.  
5.3.1 Validation level 
One of the strengths of this study is that in step 1 of the validation approach, both input 
parameters and simulation outcome of the decision model are validated. Differences in 
input parameters between AOK data and the PCa-model help to explain differences in 
simulation outcome.  
Another strength is that outcomes of claims data and model are estimated independently by 
adapting the study design of the claims data analysis to model assumptions and not the 
other way round, as it is often seen in published validation studies. That way the decision 
model is validated in the form it was originally constructed. 
A limitation, on the other hand is that quality of life indicators are not representable in 
claims data analysis; consequently, the effectiveness outcome of the decision model cannot 
be validated in this study. Only the cost outcome of the decision model is validated, which is 
of greater importance anyway, because input parameters of unit costs and assumptions on 
resource use are afflicted by a higher degree of uncertainty than effectiveness parameters 
incorporated from high quality clinical trials. 
This study is also limited in respect to its explanatory power of the model’s predictive 
validity. In the external validation presented here, the model’s structure is not validated; 
errors in the model assumptions are, thus, replicated in claims data analysis. During claims 
data analysis it became apparent that observed treatment pathways differ from the model’s 
definition occasionally; for example, utilization of laboratory services in line with the 
surveillance scheme are found in the AOK data set, but these are not considered in the 
model and are, thus, not considered as disease-related costs in claims data analysis. 
Validation of the model structure or predictive power is not the focus of this study. The 
study does, however, indicate that validation of the models structure, especially regarding 
clinical care pathways, is possible based on claims data. 
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5.3.2 Claims data set, study design, and patient cohort 
The major strength of the analysis of the AOK data set in step 2 of the validation approach is 
that actual treatment practice and costs of early-stage PCa incurred by the SHI scheme 
insured population in Germany is pictured in SHI claims data. A real-world cohort of patients 
who are treated with RP or AS is followed for complications and costs. In AOK data, analysis 
is based on exact and detailed utilization and cost information on different health care 
sectors. In contrast to the decision model, assumptions on resource use, reimbursement 
practice, and prices are not required. Overall, utilization and cost information from SHI 
claims data is reliable because actual spending on a broad range of services and technologies 
incurred by SHI is reported (52). For the validation of the model it is of importance to picture 
real-world costs in the external data source, because these are the relevant outcome 
measures in the decision model. Claims data of AOK are, thus, well suited to report these 
outcomes for validation of the PCa-model. 
In addition, the AOK dataset provides a large number of cases with PCa to select treatment 
groups from. This permits the detection of rare events, such as treatment of ED and IC with 
surgery. In a smaller cohort these events are likely to be overlooked. 
The claims data analysis replicates the study design simulated in model analysis, which is a 
major strength of the AOK data. Patients are initially treated with either AS or RP and are 
followed-up to assess complications and corresponding costs of the initial treatment. A long-
enough follow-up is chosen to replicate the first part of the decision model which represents 
treatment of early-stage PCa, not considering treatment and costs of advanced disease. 
Additionally, a unique identification number in the AOK dataset allows merging of claims 
over the study duration and health care service categories on an individual insurant level 
without loss of information due to aggregation of data. 
A limitation of SHI data in general is that no detailed clinical information is included. This is 
especially limiting in this study because no information on tumor stage or Gleason score – 
which might allow clinical classification of PCa – is available in the AOK dataset. To overcome 
this limitation, early-stage PCa is defined as absence of diagnoses of metastases. However, 
by this definition only a distinction between metastatic and non-metastatic PCa is possible. A 
sub-division of non-metastatic PCa in localized and locally advanced PCa and further 
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distinction of risk groups, as described in chapter 2.1.2, is not possible. To take this limitation 
into account, individuals receiving treatment associated with recurrence or advanced tumor 
progression are also excluded from the cohort. 
In addition to this limitation, a study by Stausberg et al. (2008) shows that reliability of 
diagnoses coding with ICD-10 GM is only fair to moderate with agreement rates between 
coders of around 50% (139). Regarding the coding quality of diagnostic codes, inpatient data 
are assumed to be more comprehensive than outpatient data (140, 141). To take the lower 
validity of outpatient diagnostic codes into account in this study, outpatient diagnoses are 
only considered when 2 consecutive codes are found in the dataset.   
Generally, only medical care and diagnoses that are relevant for SHI reimbursement are 
included in claims data; coding is biased by the underlying billing purpose of claims data. This 
effect should be equally distributed across treatment groups and not bias comparative 
outcomes. However, when complication rates or costs of single treatments are supposed to 
be representative for the general population, this limitation biases results considerably. 
Diagnosis and treatment of ED is an example in the AOK data analysis, where comparison 
with published complication rates shows that ED rates are considerably underestimated in 
claims data analysis. The reason for this is that treatment of ED, surgical or pharmaceutical, 
is generally not covered by SHI. As treatment of ED is not relevant for SHI reimbursement, 
physicians either have no incentive to code ED comprehensively despite established 
diagnosis or patients do not consult a physician in the first place. In turn, the 
underestimation of complication rates influences the validity of resource use and cost 
estimates. Unit costs of ED treatment estimated in claims data analysis are, thus, not valid 
for the validation of unit costs incorporated in the decision model. Validation of incremental 
costs, on the other hand, is not afflicted by this limitation of the claims data analysis. 
Furthermore, while date of death is coded for all insured persons in claims data, no 
information on cause of death is available. This infringes validity of claims data as death 
cannot be causally linked to a certain diagnosis or health technology utilization. Especially in 
analysis of cancer diseases, cancer-specific mortality is an outcome of interest which cannot 
be validly reported in claims data. In this study on PCa, mortality is not of primary interest 
because due to the nature of the tumor progression mortality rates are low in a study period 
of 2.5 years. Still, it would be interesting to have information on cause of death to assess 
104  Discussion 
 
 
whether the high difference in mortality rates between AS and RP found in claims data 
analysis is due to the initial treatment decision.  
Concerning the study design several limitations are present in this study. Claims data are 
available for one insurance fund with a regional focus on Baden-Württemberg only. AOK 
insurance funds tend to insure a proportionally larger population of individuals with lower 
educational status and low-skilled professions than found in the general German population, 
as described in chapter 3.3.1. This may influence outcomes of claims data analysis, because 
patients with lower socioeconomic status tend to have a higher PCa tumor grade and more 
advanced stage of disease at the time of diagnosis than patients with higher socioeconomic 
status (142). Evidence suggests that even when considering only patients with early-stage 
PCa, men with lower socioeconomic status are more likely to be treated with WW and less 
likely to receive treatment with curative intent (142). However, socioeconomic information 
is not included in such detail in the AOK claims data set to adjust for differences in 
socioeconomic status between treatment groups. Individuals in the AS-group are, thus, more 
likely to have a lower socioeconomic status than individuals in the RP-group; out-of-pocket 
payment for ED-treatment might, for example, be affected by this. However, as costs 
relevant for the SHI insured community are considered here and not out-of-pocket 
payments, socioeconomic status is likely to play a minor role in this study.  
And while by including only one insurance fund conclusions on complication rates and per 
capita costs in both treatment strategies might not be representable for the general German 
population, in this study incremental costs are relevant for the model validation, not 
absolute costs of treatment strategies (143). 
A further limitation is that the study period of 4 years allows a follow-up time of only 2.5 
years, which is too short to assess long-term complication rates and costs for individuals 
with PCa-diagnosis. Especially in case of AS, long-term costs are of interest because 
published studies indicate, as described previously, that continuously accumulating costs of 
the surveillance scheme may exceed one-time costs of the RP surgery over time. In addition, 
treatment with EBRT in case of tumor progression under AS causes common complications, 
such as bowel problems; these complications usually develop after a longer period than 
analyzed here and are hence not represented in this analysis. Costs of the AS-strategy are 
likely underestimated when only the first years after treatment initiation are examined. In 
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addition, the relatively short study duration permits a pre-observation period of only 6 
months; baseline co-morbidity may not be determined validly in this short period. In this 
study a trade-off between longer pre-observation period and longer follow-up period is 
necessary, and the longer follow-up is chosen. 
Concerning cohort selection, another limitation of the AOK claims data is that randomization 
of individuals into treatment groups is not possible, as in any other observational study. 
Hence, estimated differences between groups might be attributed to unequal distribution of 
confounding variables. This bias is reduced by matching of individuals in treatment groups 
based on age and regression analysis adjusting for co-morbidity. This bias is, however, not 
fully eliminated in this study, because the number of variables available for confounder 
adjustment is limited in the AOK dataset. Inference of effectiveness outcome of AS and RP 
(e.g. number of complications) is, thus, afflicted by a high degree of uncertainty and 
validation of the effectiveness outcome of the decision model is not undertaken in this 
study.  
Cohort selection is additionally limited by the fact that AS cannot be identified by a specific 
procedure code in the AOK claims dataset. To overcome this limitation AS is defined by a 
combination of procedures and corresponding codes, following the treatment guideline of 
DGU. However, not all of these procedures are specific for the AS scheme, such as PSA 
testing. Especially a distinction between AS and WW is difficult based on generic procedure 
codes. Analysis of coded prostate biopsies shows that only about 7% of men under AS 
receive a biopsy during follow-up. This suggests that only a minority of individuals in the AS-
group actually is under AS according to treatment guidelines in the follow-up period, while 
the remaining men may be under WW. The cohort’s life expectancy, however, is with a 
mean age of 70 years at baseline greater than 10 years and men are recommended to be 
treated with AS – according to treatment guideline; patients might actually be under AS, but 
are not surveyed by regular biopsies according to guideline. One reason for this might be 
that AS is a relatively novel treatment strategy; it may not have been performed regularly in 
Germany during the study period (2008-2011). Another reason might be that current studies 
report adverse effects of serial biopsies on erectile function and infectious complications and 
urologists may, thus, deviate from the recommended treatment protocol (82, 83). In 
consequence, the AS treatment group identified in this study is probably rather a mixture of 
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AS- and WW-patients; it might be more appropriate to refer to ‘conservative management’ 
than AS. The main purpose of this study is the validation of the PCa-model, though, and in 
the model transition probabilities for AS are extracted from a study comparing WW with RP, 
so that a mixture of AS and WW treatment effects is expected in the PCa-model, as well. 
Consequently, AOK data analysis is suitable to estimate outcomes comparable to the PCa-
model, even though it is limited in reporting outcomes of AS. 
5.3.3 Relevant health technologies and costs 
A strength of this study is that the definition of health technologies and corresponding costs 
in claims data analysis (step 3) is set closely to the definition of the decision model. The same 
diagnostic and procedure codes reported in the decision model are used in claims data 
analysis. The use of these codes allows a distinct identification of PCa-relevant health 
technologies and corresponding costs. Thereby, all health states and treatments considered 
in the first part of the PCa-model – simulating treatment of early-stage PCa – are identified 
in claims data analysis. 
A further strength of this study is that 2 different approaches are followed for the model 
validation. For one, all health technologies utilized during follow-up are considered (excess 
approach). Additionally, only PCa-relevant treatment utilization (disease-related approach) is 
analyzed. Comparison of outcomes of both approaches with model outcomes indicates 
whether the less complex excess approach is sufficient to make inferences on the decision 
model’s validity. 
Several limitations are found in the definition of PCa-relevant health technologies. For one, 
utilization of antibiotics after biopsy is not considered in the RP-group, because it is not 
considered in the decision model either. In the AS-group antibiotics are considered; the 
decision model, however, does not report a specific pharmaceutical code (PZN) in this case. 
In claims data analysis, thus, antibiotics are considered that are reported in the literature to 
be predominantly used for antibiotic prophylaxis with prostate biopsies (65, 144). Secondly, 
in outpatient treatment, costs of single EBM codes are considered as defined in the decision 
model. In claims data analysis, utilization of materials is not included in these costs; 
however, this is a relatively small portion of the total outpatient treatment costs. 
Furthermore, the treatment lump sums for GP and specialist visits are considered as disease-
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related costs if a treatment of interest (e.g. PSA or biopsy) is coded in the same quarter, as 
assumed in the PCa-model. Bias is possible in claims data analysis, though, because the 
outpatient visit could be motivated by another cause than PCa-treatment; in claims data no 
attribution of diagnoses to procedures is possible. 
Finally, analysis of PCa-specific health technologies is prone to bias in cases where resource 
use for PCa treatment cannot be specifically circumscribed (e.g. GP visits). As it is the aim of 
this study to validate model outcomes, definition of PCa-specific costs is adapted to the 
model’s definition. Disease-related costs may not represent all costs incurred by the SHI fund 
for the treatment of PCa, but they reflect the costs assumed in the decision model, which is 
of greater importance for this study. 
5.3.4 Statistical methods for claims data analysis 
Another strength of this study, concerning statistical methods of claims data analysis 
described in step 4 of the validation approach, is that matching of individuals by age makes 
treatment groups more comparable and thereby replicates a characteristic of the decision 
model’s cohort, where individuals in the AS- and the RP-group are assumed to be of same 
age. Standard statistical methods, such as regression analysis, are used to adjust for co-
morbidity and thereby further ensure comparability of claims data and model outcomes. 
Additionally, recycled predictions method is employed to estimate absolute values of 
complication rates and costs per treatment strategy; bootstrapping is used to calculate 
variability of estimates via 95% CIs. 
Regarding analysis of claims data, a limitation is that matching of treatment groups by age 
results in a considerable loss of individuals in both treatment groups. Especially in the AS-
group, where 17 patients (about 14%) are lost due to matching, representativeness of this 
treatment group is questionable. However, to ensure comparability between treatment 
groups it is necessary to disregard patients with a differing, usually higher, age in the AS-
group than in the RP-group; according to treatment guideline, patients with a life expectancy 
smaller than 10 years are not eligible for AS treatment. Still, a greater patient heterogeneity 
is found in the claims data cohort than in the model, especially regarding co-morbidity, 
because the variables available for adjustment and matching are very limited in the AOK 
dataset.  
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Additionally, use of CCS for adjustment is limited; when no diagnosis is coded in the pre-
observation period it cannot be differentiated whether the individual is free of disease or an 
existing illness is just not coded in the SHI scheme. Furthermore, in excess costs analysis CCS 
is not able to adjust for co-morbidities with high outpatient and pharmaceutical costs which 
are not related to PCa-treatment, because the Charlson index intends to assess inpatient 
mortality.  
Furthermore, dependency of data due to matching is not accounted for by using conditional 
regression analysis. Dependency of data is very low, though, as matching is only performed 
for age; also no longitudinal analysis of single individuals is intended. 
Outcomes of excess cost analysis are limited in their informative value because absolute 
costs do not reflect PCa treatment-specific costs. By adjusting for co-morbidity, differences 
in costs can be attributed to the initial treatment strategy, though. Disease-related cost 
analysis overcomes this limitation, despite its own pitfalls. The most severe limitation of 
disease-related cost analysis is the small number of observations which limits the validity of 
single cost estimates, especially in cases where technologies are utilized by only 1 or 2 
individuals, such as surgical procedures for ED and IC. As a result, calculation of costs for 
single procedures may not be representative for certain health technologies in this study. To 
mitigate this limitation health technologies are combined in cost groups so that observation 
numbers increase. 
Another limitation, which is common in the analysis of health care utilization, is that 
resource utilization is skewed; a small number of individuals utilizes health technologies and 
incurs substantial costs, whereas the remaining cohort has no utilization. In this case, 
unadjusted means and STDs have no informative value. To account for this problem, two-
part regression models are employed in this study.  
5.3.5 Changes to the decision model 
A further strength of this study is that access to the originally published Markov model in 
Treeage is possible to conduct changes described in step 5. Thus, information is available for 
the model validation which is not reported in the publication of the PCa-model, for example 
codes defining PCa-related treatment. By the use of this information, outcomes estimated in 
claims data analysis are more comparable to outcomes of model simulation than without 
this additional information. The additional information also allows adapting the claims data 
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cohort as closely as possible – given available variables – to the model’s cohort 
characteristics. 
Access to the decision model also makes it possible to conduct additional analyses in the 
model assessing resource use and costs of single treatments, which are not reported in the 
original publication of Koerber et al. (2014); cost differences in specific treatments explain 
overall cost difference between treatment strategies. The total cost difference between AS 
and RP, for example, is almost exclusively determined by the cost difference found in RP 
surgery. The structure of the model itself is not changed in this analysis, which allows a 
validation of the originally published model.   
Generally, a thorough understanding of model structure and assumptions facilitates the 
explanation of differences between AOK and model estimates, which is only possible when 
the original model can be retraced. 
Furthermore, it is a strength of this study that in Treeage simulated model data are analyzed 
in SAS software. This way it is possible to calculate measures of uncertainty, such as CIs for 
incremental costs, which are not available in Treeage. Graphical presentation of model 
outcomes in form of bar charts and histograms is possible, too. Import of model data in SAS 
also allows formatting of data in a layout which makes calculation of differences between 
AOK and PCa-model outcomes as well as statistical hypothesis testing possible. 
A limitation in the model analysis concerns the age distribution assumed in the model. As 
described previously the age distribution in the decision model needs to be adapted to the 
claims data cohort for a valid comparison of outcomes. Thus, it is assumed that all men in 
the model start treatment at the age of 70 years which is the mean age of the AOK cohort. 
This is, however, a simplification of the age distribution found in claims data; to be more 
precise the exact age structure of the AOK cohort should be represented in the model. The 
model by Koerber et al. does not allow incorporation of an age distribution at treatment 
initiation, though, and to change this assumption the model structure would have to be 
changed fundamentally. To estimate the impact of this limitation on outcomes, sensitivity 
analyses varying age at treatment initiation are conducted, as described previously. Results 
of the sensitivity analyses show that the overall agreement between AOK and model 
estimates is not affected by age at treatment initiation. 
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Another limitation in the model analysis is that the microsimulation cannot simulate 
different observation numbers for treatment strategies as in the claims data analysis where 
the RP-group includes twice as many individuals as the AS-group. The microsimulation is 
consequently simulated with 321 individuals in each treatment group; the AS-group in the 
microsimulation is thus 3 times larger than the AS-group in the claims dataset and the RP-
group 1.5 times larger, respectively. In addition, the number of observations in 
microsimulation is so low that not every pathway through the model can be simulated and 
results between cost groups may vary because of differences in pathways and not 
differences in costs. To take this limitation into account Monte Carlo simulation is performed 
which evaluates the magnitude of the parameter uncertainty. 
5.3.6 Comparison between model and claims data 
One of the strengths in the comparison of claims data and model, described in step 6 of the 
validation approach in this study, is that graphical presentations as well as statistical 
methods are used to quantify the agreement between AOK and model outcomes. Simulated 
(bootstrapped) AOK samples and PCa-model samples are merged to calculate cost 
differences. Incremental costs of treatment strategies are compared between AOK data and 
model which is of most relevance for a decision-maker.  
Furthermore, comparison of cost estimates is based on 2 different approaches; disease-
related as well as excess costs are estimated in claims data analysis. Disease-related cost 
analysis allows the validation of costs of single treatments simulated in the model with 
outcomes of claims data analysis. In disease-related analysis, resource use of treated 
individuals and unit costs of PCa-relevant health technologies estimated in claims data 
analysis are compared with input parameters incorporated in the model. This validation of 
input parameters helps explain differences in per capita costs. 
Additionally, sensitivity analyses are employed to assess the impact of claims data cohort’s 
characteristics (newly diagnosed PCa-cases) and model cohort’s assumptions (age at 
treatment initiation) on agreement between AOK and PCa-model outcomes.  
A limitation, on the other hand, is that the explanatory power of the comparison between 
AOK data and PCa-model might be limited by greater patient heterogeneity in the claims 
data cohort than in the model, especially regarding co-morbidity. Additionally, the 
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reproduction of treatment strategies as defined in the model is limited in claims data which 
also infringes the informative value of the comparison. 
Outcomes of the comparison are also affected by the way mortality is accounted for. In 
claims data analysis all resource use and costs accumulated until death are considered. In 
model simulation, on the other hand, costs of individuals dying during follow-up are not 
added to costs of the cohort. As mortality rates are small, this limitation minimally affects 
outcomes of the comparison between claims data and decision model, though. 
Another limitation, regarding the sensitivity analysis where inclusion criteria for the claims 
data cohort are changed, becomes apparent: incidence of PCa-diagnosis is established in the 
pre-observation period; this period might be too short to ensure that PCa has not been 
diagnosed before study initiation, though. As overall agreement between AOK data and 
model outcome does not change, this limitation seems to have no notable influence on 
results. 
Furthermore, quantitative comparison is limited to per capita costs in this study. Difference 
in utilization probability between model and claims data is not tested statistically because 
the simulation of the data needed for the quantitative comparison is extremely complex in 
the model by Koerber et al. (2014). 
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5.4 Practical implications 
5.4.1 Generalizability of validation approach 
The approach to claims data based validation described in chapter 3.1 can be applied for a 
variety of model validations. The strengths and limitations of claims data based validation 
discussed in chapter 5.3 may, however, not apply in every case. Generalizability of the 
approach to model validation based on claims data is assessed exemplarily for 2 cases: first, 
the validation of models comparing treatment for indications other than PCa and, second, 
validation based on administrative data sources other than German SHI data.  
Examples of an adaptation of the validation approach to a variety of indications are 
highlighted in the following. 
Concerning the decision on the validation level, effectiveness measures may be validated as 
well if outcome is replicable in claims data – contrary to the validation of the PCa-model 
where effectiveness outcome is measured in QALYs. Outcome measures concerning the 
utilization of health technologies can generally be reproduced validly in claims data. Health 
care utilization is, for example, an important measure of effectiveness in the treatment of 
cartilage defects in the knee, where the aim of novel treatment options, such as autologous 
chondrocyte implantation, is the prevention of joint replacement (145). Effectiveness 
measured as the number of replacement surgeries is, thus, an outcome which can be validly 
analyzed in SHI claims data.  
Concerning cohort selection and study design, validation based on claims data is only useful 
if the indication of interest is validly coded in the dataset. The example of ED diagnosis 
shows that diseases whose treatment is not or only partially covered by SHI may not be 
coded validly in SHI data. Furthermore, severity of disease is not coded in SHI data and may 
only be deduced from diagnoses of co-morbidity – as in this study where advanced PCa is 
defined by diagnosis of metastases – or coding of relevant procedures. Diabetes is, for 
example, an indication where severity of disease can only be inferred from the intake of 
insulin and the co-morbidity status (146). The same applies to parameters describing patient 
characteristics which are essential to replicate the model’s cohort; an example is smoking 
status which is not coded in SHI data, but is of paramount importance in studies on lung 
diseases (147). Furthermore, when indications are evaluated in a decision model where the 
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cost and effectiveness outcome can only be determined in a lifetime perspective, SHI claims 
data usually cannot provide valid estimates; due to technical and data protection issues it is 
generally not possible to analyze individual patient data with a lifetime perspective. An 
example where a long time of follow-up is necessary to assess differences between 
treatment groups, is the treatment of cartilage defects in the knee avoiding joint 
replacement mentioned above; replacement surgery usually becomes necessary 10 to 20 
years after the initial therapy (145). 
Regarding the definition of disease-relevant health states and technologies, adaptations of 
the validation approach presented for the PCa-model to the indication of interest might also 
be necessary. On the one hand, the validity of the claims data estimate of technology 
utilization depends on how detailed the definition of disease-related health technologies is 
reported in the decision model. If no information on codes for health technologies is 
provided in the model, it is difficult to accurately replicate the analysis of resource use and 
costs in claims data analysis. On the other hand, treatment of the indication of interest 
might not have any specific codes in the SHI scheme or it is not covered and thus not coded 
by SHI at all; again the example of ED treatment is applicable here. 
Statistical methods for analysis of SHI claims data must be adapted to the indication of 
interest. Matching techniques might, as shown in this study, result in a loss of cases; when 
indications with a low number of observations, for example rare diseases, are studied, 
adjusting for confounding in regression analysis might be the better option (28). 
Changes to the model structure and additional analysis conducted with the decision model 
might be necessary, depending on the cohort characteristics and the study design chosen for 
the validation. Apart from adaptation of age, as in this study, this might include change of 
gender distribution in the decision model or change of the model’s perspective from a 
societal to a SHI insured population perspective. 
Adaptation of the validation approach to administrative data sources other than the German 
SHI scheme is highlighted in the following, using the examples of the US Medicare/ Medicaid 
claims database and the UK General Practitioners Research Database. The UK GP Research 
Database includes medical information from inpatient and outpatient care as well as 
pharmaceutical prescriptions which converge at the GP in the UK national health service 
system (148). US Medicare covers inpatient, outpatient, and pharmaceutical claims of 
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individuals 65 years of age and older, whereas Medicaid covers disabled individuals; dual 
eligibility is possible (149). 
The extent of clinical information included in the claims dataset has a particularly strong 
influence on the practicality of claims data for the validation of effectiveness measures. In 
the GP research database, for example, laboratory values are available and access to original 
medical records is possible (148), which would allow classifying PCa tumor stage based on 
PSA value and Gleason score, in contrast to SHI claims data. 
Regarding the selection of a patient cohort reflecting the model’s cohort, the UK GP research 
database includes a population-based dataset which is representative of the UK population 
and contains a large number of individuals (about 3 million) (148); based on the UK GP 
database, selection of a cohort validly reflecting model assumptions is very likely. US 
Medicare/ Medicaid, on the other hand, covers a population which is not representative of 
the general US population due to eligibility criteria; it might, thus, be more difficult to select 
a cohort equivalent to model assumptions (150). Information on socioeconomic status is not 
included in the UK GP research database, which biases cohort selection according to model 
assumptions. 
To identify relevant health states and health technologies in the administrative data source, 
it is necessary that these can be uniquely identified. This is possible in both the UK GP 
research database and US Medicare/ Medicaid database, as diseases and procedures are 
identified with unique codes, similar to German SHI data (148, 150). In the UK GP research 
database, however, no information on health technology utilization outside the GPs’ 
responsibility is included in the dataset, which leads to similar bias as in this study, where 
not all health care utilization is covered and, thus, not coded by SHI. 
Other aspects of claims data discussed previously, for example confounding and data 
protection issues as well as disease-specific difference in validity of claims data, are 
applicable to all insurance systems.  
5.4.2 Implications for model validation 
For the validation of decision models this study generally implicates that access to the 
validated decision model is necessary, especially, if model assumptions, such as age 
distribution and run time, have to be adapted to the external data source to generate 
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comparable outcomes. Often additional analyses of the decision model are necessary to 
produce data in a format comparable to data of the claims data source. 
Furthermore, it would facilitate validation of decision models based on claims data, if 
resource utilization and costs relevant for the SHI or SHI scheme insured community 
perspective are distinctly displayed in decision models, so that a calculation of the SHI 
perspective, in addition to the societal perspective, is simplified. 
It is shown in this study that the relatively less time-consuming excess approach is able to 
validate total incremental costs of the decision model by itself; the results are comparable to 
the more complex disease-related approach where health technologies are defined 
according to the model’s definition of disease-related technology utilization. If in a validation 
based on claims data the concordance of claims data cohort and model cohort can be 
ensured and statistical techniques are employed to make treatment strategies comparable 
(matching, regression analysis), an excess cost approach might be sufficient to validate total 
costs. This study, however, shows that even if agreement between estimates of total costs is 
sufficient to assume that the model simulates real-world costs, this might not be the case for 
costs of individual treatments considered in the model. The disease-related approach is 
useful in this case to validate incremental costs of single treatments. If in a model validation 
resource utilization and costs of individual health technologies are not relevant, the less 
complex excess approach may be suitable. 
Concerning the results of the validation, it is apparent that results are subject to 
interpretation. Graphical and statistical presentation can only indicate an agreement 
between outcome simulated in the model and outcome observed in the external data 
source. In addition, the agreement between model and claims data has to be interpreted in 
light of the uncertainty afflicting the individual parameters.  
Whether this agreement is sufficient to infer that the model simulates real-world outcomes 
validly depends greatly on the limitations of the external data source, most of all limitations 
of the claims data analysis in replicating the model’s structure and cohort assumptions. SHI 
data may be the gold standard for real-world resource use and costs, if however the study 
design (e.g. length of follow-up) and cohort (e.g. patient characteristics and treatment 
groups) of the decision model cannot be replicated in the claims data, the estimates of 
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resource use and costs, in turn, are not comparable to the model outcomes and, thus, not 
suitable for validation. 
5.4.3 Implications for industry 
A potential application of the validation of decision models based on claims data is described 
exemplarily in the context of the integration of novel health technologies in the SHI system’s 
benefit catalogue. 
The clinical effectiveness and costs – key components of a new medical technology’s value – 
are usually uncertain at the point of coverage decision-making by a health care payer. This is 
in part due to the fact that market-approval agencies ask for evidence regarding safety and 
efficacy, while coverage decision makers are predominantly interested in effectiveness and 
real-world costs. Decision models may be employed, in this context, to incorporate available 
evidence and predict real-world effectiveness and costs; these predictions of effectiveness 
and costs are, however, still subject to high variability due to the uncertainty in the 
underlying evidence (151). 
Under such uncertainty the decision maker may reject coverage and thus deny patients 
access to potentially beneficial technologies. A positive coverage decision, on the other 
hand, may lead to reimbursement of potentially clinically or cost ineffective medical 
technologies and strain already tight budgets (152). To address this uncertainty, market 
entry can be accompanied by arrangements where further evidence regarding the 
performance and utilization of the technology is collected alongside use; new evidence can 
either be incorporated in the decision model or used to validate the predictions of the 
original model. That way the final coverage decision can be delayed until sufficient evidence 
is available, while enabling early patient access to novel technologies (45). These schemes 
are usually referred to as “managed entry agreements” (MEA) (Figure 5-1) (153). In 
Germany, since the introduction of the Healthcare Provision Act (GKV-
Versorgungsstrukturgesetz) in 2011, novel examination and treatment methods can be 
covered by SHI on the condition that clinical data are gathered alongside use in clinical 
practice (51).  
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Figure 5-1: Typology of managed entry agreements 
As MEA rely on the collection of information, the question arises where to find suitable 
evidence to validate the predicted outcomes of the model. Original data collected within 
randomized controlled trials are seen as the gold standard for evidence development. 
However, they inhibit limitations regarding evidence on effectiveness and cost-effectiveness 
in clinical practice, which is of primary interest for decision makers (38, 39). Original data 
collected within registries may overcome some of these problems, but have their own 
distinct limitations (42, 154). In both cases, data collection is likely to incur high costs to 
manufacturers or health care payers. Given the already high costs of clinical research in the 
development of medical innovations (155), there is a risk that the costs of evidence-
collection exceed the potential value associated with the additional evidence. A valid option 
for the validation of decision models in line with a MEA are, consequently, claims data (156). 
Especially, when MEA are formed between a manufacturer of a novel technology and a SHI 
fund, it is of interest for the SHI fund to validate the models predictions with a patient cohort 
reflecting the funds insured community; the SHI funds own claims are obviously the most 
valid data source to achieve this. Use of claims data is useful for the validation of decision 
models conducted in line with MEAs which concern not only one insurance fund but the 
whole SHI insurance system, too. The relevant patient cohort, in this case, is the SHI scheme 
insured community. 
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The suitability of claims data is especially high for agreements that concern utilization or cost 
outcomes of a novel technology. In agreements where the level of reimbursement is 
dependent on utilization and cost outcomes – so called risk-sharing agreements – validation 
of these outcomes based on claims data is useful.  
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6 Conclusion 
To answer the research question ‘Are claims data of health insurance funds suitable to 
externally validate decision-analytic models?’ this study proposes a step-wise validation 
approach. Applicability of the validation approach is assessed on the exemplary validation of 
a Markov model comparing treatment of localized PCa based on claims data of a large 
German SHI fund. Strengths and limitations of claims data based validation is discussed for 
each validation step. Generalizability and implications of claims data based model validation 
are presented. 
Concerning the medical point of view, the analysis indicates that in the first years after 
treatment initiation costs of AS are significantly lower than the costs of radical therapy with 
RP for early-stage PCa – predominantly due to the high initial costs of the RP surgery. 
Treatment of complications following initial therapy has a very small impact on costs, albeit 
ED and IC have a substantial impact on patients’ quality of life. These results are consistent 
in the 2 different cost analysis approaches presented in claims data analysis – excess cost 
and disease-related cost analysis – and are predicted by the decision model, as well. 
Concerning the validation of the decision model, a degree of an overall agreement between 
the AOK data and PCa-model outcome is found which is sufficient to assume that the model 
simulates short-term real-world resource use and costs of AS compared to RP validly. The 
outcomes of excess cost analysis alone are able to validate total incremental costs in this 
study, which would make the more extensive disease-related analysis unnecessary; disease-
related analysis is, however, useful to validate incremental costs of individual treatments of 
PCa. Validation of individual treatments shows that resource use and costs simulated in the 
decision model are most valid for inpatient care, whereas outpatient care differs significantly 
from observed outcomes in claims data. 
The exemplary model validation reveals strengths and limitations of claims data for model 
validation, which are characteristic for claims data based model validation in general.  
Claims data are able to provide evidence on real-world resource utilization and, with 
limitations regarding clinical information, effectiveness of a wide range of indications and 
treatments in a large patient cohort. Validation based on claims data is especially suitable 
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when the decision maker, interested in the validity of the model in question, is the insurance 
fund providing access to the claims data; the claims data cohort is representative of the 
insured population of the insurance fund. Claims data may be regarded as the gold standard 
for real-world evidence on resource utilization and costs in this case. Furthermore, use of 
claims data for the validation of decision models is less costly and time consuming than 
collection of primary evidence in RCTs.  
Suitability of claims data based validation is, however, limited concerning the replication of 
the decision model’s structure and cohort assumptions. For one, the identification of distinct 
health states is limited, because clinical information, such as laboratory values or tumor 
stage, is not included in SHI claims data. Also, due to non-randomization and a restricted 
number of variables available to adjust for confounding, comparability of treatment groups 
is limited in SHI claims data analysis; claims data analysis may not reflect model analysis 
which is usually based on randomized trials. Furthermore, distinct identification of health 
technology utilization and corresponding costs is not possible, if the technology of interest is 
not specifically coded. Claims data are, generally, collected for billing purposes; diagnoses 
and technology utilization are only coded if they are relevant for reimbursement, which 
biases outcomes of model validation in cases where treatment is not covered by the 
insurance fund. 
The suitability of claims data for the validation of the decision model of interest eventually 
depends on the ability of the claims data source to reflect the model’s patient cohort and 
outcome measures. If study design and cohort assumptions of the decision model cannot be 
replicated in the claims data, the estimates of resource use and costs, in turn, are not 
comparable to the model outcomes and, thus, not suitable for validation.  
Weighing up of strengths against limitations of claims data based validation has to be made 
for each case independently. The proposed validation approach indicates critical aspects in 
the validation based on claims data, which may support researchers and decision makers in 
their decision on the suitability of claims data.   
Further research is necessary to assess the applicability of the validation approach in models 
with indications other than PCa and validation based on other external data sources, for 
example registry data.  
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Methodological aspects of the comparison of claims data and model outcomes, such as 
statistical techniques that test difference between estimates, need to be refined. As seen in 
this study, the validity of statistical methods, for example, depends on the presence of 
paired observations in the two data sources. A systematic assessment of various statistical 
methods for different types of external model validation would be a useful guidance for 
model validation.   
It is also interesting to assess the practical implication of claims data based validation for 
industry. For example, the practicality of claims data based model validation for the 
management of novel health technologies in the SHI benefit catalogue should be assessed in 
further research. 
Finally, further research is needed to assess whether claims data are suitable for model 
validation apart from external parameter validation. This study indicates that validation of 
model structure is possible based on claims data. Studies on the suitability of claims data to 
assess predictive validity of decision models might be interesting, as well.  
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RP with complications     ED 
   
IC     Monitoring after RP 
   
Figure A-1: Distribution of disease-related costs in cost groups (€), by treatment strategy and 
data source 
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RP w/o complications     EBRT 
   
Stricture     Surgery for ED 
   
Surgery for IC     Urosepsis 
   
Figure A-1: Distribution of disease-related costs in cost groups (€), by treatment strategy and 
data source (continued) 
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Figure A-1: Distribution of disease-related costs in cost groups (€), by treatment strategy and 
data source (continued) 
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   IC     Monitoring after RP 
   
Figure A-2: Histogram of simulated, disease-related incremental costs (€), by cost group and 
data source 
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Figure A-2: Histogram of simulated, disease-related incremental costs (€), by data source 
(continued) 
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Figure A-2: Histogram of simulated, disease-related incremental costs (€), by data source 
(continued) 
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